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Discussions with rugby team doctors and physiotherapists suggest that the 
prevalence of patellar tendinopathy (PT) in rugby populations is increasing. 
However, from a review of the published literature patellar tendinopathy is not a 
condition commonly reported in rugby athletes. PT can have serious consequences 
for an athlete, which may even be career ending. Some of the characteristic 
ultrasound features of tendinopathy can be seen prior to an athlete developing 
symptoms of the disease. This would suggest that players should be regularly 
examined with ultrasound. However, such an approach is prohibitive because of the 
cost, both of the equipment and the professional expertise required. Therefore, a 
screening method, which did not involve the use of expensive equipment and trained 
personnel, and which could predict the presence of patellar tendon disease, especially 
when the athlete is asymptomatic, is highly desirable. To date, such a screening 
method does not exist. The aims of this study were to investigate, in a sample of elite 
academy rugby players: 1) the prevalence of patellar tendinopathy, 2) the prevalence 
of asymptomatic patellar tendon disease on ultrasound imaging, 3) whether patellar 
tendon disease is associated with weight or playing position, 4) whether vertical 
ground reaction force (VGRF) data from drop-landing tasks can predict the presence 
of patellar tendon disease and avoid the need for costly ultrasound screening. 
 
A group of academy rugby players from Wales (n=46) received a combination of 
clinical and ultrasound examination of their patellar tendons. Ultrasound examination 
was used to establish the presence of a patellar tendon abnormality (PTA). VGRF 
data were measured during a drop-landing task from a 30 cm platform situated 
immediately behind a portable force plate. Peak VGRF and loading rate VGRF data 
were recorded. 
 
Sixteen players (35%) were found to have patellar tendon disease (a PTA) on 
ultrasound imaging. The prevalence of clinically apparent PT, with associated 
ultrasound changes, in this cohort was found to be 15.2% (n=7). There was no 
	   iii	  
difference in either body mass or playing position between those players with 
patellar tendon disease and those with healthy patellar tendons. VGRF data from a 
drop-landing task was unable to predict the presence of patellar tendon disease. 
 
The study suggests that the prevalence of patellar tendon disease is higher than 
previously reported. The study does not support the use of VGRF to predict the 
presence of patellar tendon disease. Due to the high prevalence of disease, and the 
potential consequences for those affected, the study recommends further research 
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Chapter 1. Introduction to the Study 
 
 
This study is about patellar tendinopathy (PT) in rugby players. It is a condition that 
is thought to be increasingly common and difficult to diagnose outside a clinical 
environment. It can be present prior to an athlete experiencing symptoms of the 
disease. Once established, it can have significant consequences for the player and, in 
a worse case scenario, patellar tendinopathy can end an athlete’s playing career. 
Diagnosis of PT is made by clinical and ultrasound examination of the patellar 
tendon (the gold standard) which is not often routinely available. This means that PT 
can deteriorate undetected, which makes subsequent treatment and management 
more prolonged with possible devastating consequences for the athlete. In this study, 
an attempt is made to determine the prevalence of PT in a sample of age-grade rugby 
players attached to academies; and to investigate whether it is possible to predict the 
presence of PT by using a test that is simpler to administer than the gold standard.  
 
Patellar tendinopathy is a common sporting overuse injury. The most widely 
referenced study on PT prevalence is by Lian et al. (2005) who reported that the 
overall prevalence of patellar tendinopathy in elite sports (not including rugby) is 
approximately 14%. PT is more commonly seen in sports that are characterised by 
high demands on leg extensor speed and power (Visnes et al., 2012). This includes 
sports that involve high frequency jumping activities or those which involve quick 
changes in direction (cutting). It is thought that amongst other factors, this is due to 
high patellar tendon load1 (Bisseling et al., 2007; Cook & Purdam, 2009; Scott et al., 
2013). Thus, the more commonly researched sports for this condition include 
volleyball, netball, basketball and soccer. Rugby, which has all of the above 
characteristics, is devoid of studies into patellar tendinopathy and therefore the 
prevalence of patellar tendinopathy is unknown in rugby players. Chalmers (2002) 
argues that from a “national sports organization” perspective, injury prevention 
research should be targeted towards injuries that are common, that prevent elite 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 The sum of all the forces and moments acting on a body [the patellar tendon](Kent, 1994) 2	  Coombes et al. (2009); Lewis (2010); Malliaras & Cook (2011); Campbell et al. (2013). 
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athletes from competing and earning revenue for their sport, and those that are the 
greatest barriers to personal achievement. Several oral reports from sports doctors 
working within rugby union in Wales claim that the prevalence of patellar 
tendinopathy is increasing (personal communication Jones, 2010; Ridgewell, 2012). 
However, if one takes the view that “the pleural of anecdote is not data” (Frank 
Kotsinis), a study in to the prevalence of PT in rugby is warranted.  
 
Despite rugby being a popular, professional sport worldwide, there are few studies 
that have established either the prevalence of patellar tendinopathy in rugby players 
or a mechanism for predicting its presence. This study attempts to address these gaps 
in understanding. It is expected that the prevalence of patellar tendinopathy in rugby 
athletes would be similar to that of the sports which have been reported on, because 
rugby involves similar movement patterns. 
 
In order to undertake a study of PT in rugby players, the pathogenesis of the 
condition and its effect on athletes needs to be understood. The literature review that 
follows addresses the pathogenesis and symptomatology of patellar tendinopathy and 
examines the insidious nature of symptom development. Studies that have examined 
the condition are reported on. Current practice in relation to diagnosis is discussed 
and the impact of PT is also explored. The conclusions inform both the study 
questions and design. 
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As this study is about patellar tendinopathy and its potential impact on the career of 
elite rugby players, this chapter begins with an analysis of the pathological changes 
that can occur as a result of overuse. It then goes on to provide an analysis of what is 
currently understood about both the prevalence and aetiology of PT and its 




2.2 Search strategy 
 
A comprehensive literature review of tendinopathy, with specific emphasis on 
patellar tendinopathy was undertaken. The search strategy involved a free text search 
across the MEDLINE database.  Academic search engines (such as Google Scholar) 
were key because no one database contained all the relevant journals. Areas such as 
clinical medicine, biomechanics, sport injury and screening etc. are not all contained 
in one database. Whether searching MEDLINE or search engines, the same search 
terms were used. Initial search strings were expanded as different evidence was 
accumulated. For example, an initial search on tendinopathy expanded subsequently 
to include ‘degenerative’ and ‘inflammatory’ in the string. There were no time 
parameters in the search. Only publications that were in English were included. 
Traditional search engines were used to locate grey literature such as technical 
reports from working or research groups. Key search terms included, but not limited 
to, ‘tendinopathy’, ‘tendinopathy rugby’, ‘patellar tendinitis’, ‘jumper’s knee’, 
‘patellar tendinopathy’ and ‘patellar tendinopathy rugby’. Searches were repeated 
throughout the course of the dissertation to alert the researcher to new publications. 
This proved to be crucial as a study very similar to the one reported here was 
published in 2013. Likewise a paper, which suggested that some of the damage seen 
in tendinopathy might be mediated through inflammatory processes, was also 
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published in 2013. Social networks were used to alert the researcher to new 




2.3 The Patellar Tendon 
 
The patellar tendon is an extension of the quadriceps femoris tendon. It extends from 










The patellar tendon, along with the quadriceps muscle and tendon, the patella and the 
retinaculum (the strong band of connective tissue that holds the patella in place), 
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2.4 Definition of Patellar Tendinopathy 
 
Patellar tendinopathy is a clinical condition characterised by activity related, anterior 
knee pain (Brukner et al., 2007). This pain is accompanied by tenderness to palpation 
over the patellar tendon or its attachments, particularly over the inferior pole of the 
patella. It is one of the most common of the chronic tendinopathies (Maffulli et al., 
2003). The term “patellar tendinopathy” has become the preferred term for the 
conditions previously described as “jumper’s knee” or “patellar tendinitis” (Khan et 
al., 1999). This change in nomenclature reflects the change in understanding of the 
pathogenesis of the condition in the 1990s. The consensus at that time was that 
tendinopathy was no longer thought to be inflammatory in nature, but degenerative. 
Thus, the term “tendinitis” is a misnomer and this has been the prevailing 
understanding of the condition for circa 20 years. In 2009, Cook and Purdam 
reported on a critical review of histopathological and imaging studies into 
tendinopathy. Their conclusions supported the prevailing opinion that tendinopathy 
is degenerative in nature. Recently, however, Rees et al. (2013) queried whether: 
 
1. At least some of, the damage seen in tendinopathy was mediated by elements 
of the inflammatory process and 
2. The prevailing understanding needed to be challenged? 
 
They felt that to refer to tendinopathy as degenerative only was an 
oversimplification. This premise was based upon a number of small-scale studies that 
demonstrated microscopic evidence of inflammation being present in tendinopathy 
(Schubert et al., 2005). Also in 2013, the International Scientific Tendinopathy 
Symposium consensus statement on exercise related tendinopathy was published 
(Scott et al., 2013). Two of the authors of Rees et al., (2013) were also contributors 
to the consensus statement in which, it was accepted that, “structural degeneration of 
the load-bearing matrix [of the tendon] is a key feature, with an absence or minimal 
presence of inflammatory cells”. Nevertheless, Rees et al. (2013) argue that the 
contribution of inflammatory processes as a key component of tendon damage needs 
to be appreciated. The challenges posited by Rees et al. (2013) to the current 
understanding of the condition must be given consideration (particularly when 
successful treatment is difficult). However, until further appropriate research is 
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available, for the purposes of this study, tendinopathy is regarded as mainly 




2.5 Pathogenesis and Symptomatology 
 
Tendinopathy, viewed as a degenerative process, is most often described as a 
mechanism of dysrepair (failed healing) in response to chronic overload of the 
tendon. Both extrinsic factors (e.g. sport surface, load) and intrinsic factors (e.g. 
biological age, sex, genes, biomechanics) have been implicated in predisposing to 
injury but according to Cook & Khan (2008), who reviewed existing studies, the 
pathoaetiology is not clear. However, there does seem to be a consensus that load is a 
critical factor (Bisseling et al., 2007; Cook & Purdam, 2009; Scott et al., 2013). 
Given this common understanding, Cook & Purdam (2009) examined the existing 
evidence base for load as a factor in tendinopathy. In an attempt to understand this 
relationship, 83 papers were reviewed (of which they had contributed to the 
authorship of n=12). The studies included in their paper fall into three broad 
categories:  
1. The histopathological changes associated with tendinopathy  
2. The outcome from various treatments for tendinopathy 
3. The way in which the disease progresses over time (including periods of rest 
or reduction of load). 
 
The conclusion from the analysis of the included studies is that tendon pathology 
might be conceptualised as a continuum, which Cook & Purdam (2009) represent as 
a model (figure 2.2). The model is described and critiqued in some detail here 
because it captures existing theories about the way in which the disease progresses 































Figure 2.2: Theory of pathology continuum. Reproduced from Cook & Purdam (2009) 
 
 
A model is an abstraction of reality, the usefulness of which is its ability to be used 
as a comparison for reality. This model is described in detail below. Although citing 
load as the main catalyst for degenerative tendinopathy, Cook and Purdam (2009) 
acknowledge that the pathoaetiology is “almost certainly” modulated by a range of 
other factors. The model is frequently cited (see footnote)2, including in the 
International Scientific Tendinopathy Symposium consensus statement (Scott et al., 
2013).  
 
  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2	  Coombes et al. (2009); Lewis (2010); Malliaras & Cook (2011); Campbell et al. (2013). 
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Cook and Purdam’s (2009) model describes three stages along this pathology 
continuum: reactive tendinopathy, tendon dysrepair and degenerative tendinopathy. 
The addition or removing of load is thought to be the primary stimulus that drives the 





Reactive tendinopathy is the first stage along the continuum, a result of acute tensile 
or compressive overload of the tendon e.g. an academy rugby player who 
dramatically increases the amount of training sessions performed per week. The 
tendon adapts by becoming thicker, this reduces stress by dissipating the force over a 
larger surface area. This area of thickening can be seen on ultrasound scanning of the 
tendon (as will be discussed). The athlete in question may exhibit patellar tendon 
swelling and pain. Cook and Purdam described reactive tendinopathy as a short-term 
adaptation to overload. It is thought that tendons in this stage of the continuum can 
revert back to normal if a sufficient reduction of load occurs or there is sufficient rest 





The second stage along the continuum is termed tendon dysrepair. It is thought to be 
a failed healing response to reactive tendinopathy. This can occur when there is 
insufficient removal of load i.e. continuing to train at high intensity (volume or 
frequency) with inadequate rest periods. This would mean that the pattern of training 
described in the reactive tendinopathy stage persists. In similar fashion to academy 
rugby players, Reeser et al. (2006) argued that in volleyball players, the risk of 
developing patellar tendinopathy is higher at the time when players are promoted 
from junior level to senior level. The abrupt move from a relatively safe training 
environment, which might involve practice two or three days a week to an elite sport 
environment; which has a frequent, often daily, structured programme of activity 
(training or playing); results in a high risk of developing patellar tendinopathy.  
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Tendon dysrepair is characterised by a marked increase in protein production 
(collagen and proteoglycans). The increased proteoglycans result in separation of the 
collagen fascicles and disorganisation of the usually well-structured matrix. The 
relevance of this will become apparent later when describing the gold standard for 
diagnosing patellar tendinopathy, which involves ultrasound scanning of the tendons 
that, at this stage, will show the areas of collagen disorganisation as focal areas of 
hypoechogenicity3. Cook and Purdam (2009) acknowledge that this stage of 





The most extreme end of the continuum is termed degenerative tendinopathy. It is a 
progression of the changes seen in the previous stage. The areas of disorganisation of 
the matrix are larger. This is reflected as larger areas of hypoechogenicity on 
ultrasound imaging. It is thought that the potential for reversibility from this stage is 
limited. If the degeneration is significant enough, the tendon has the potential to 
rupture. Where there is degenerative tendinopathy, the athlete would require 
significant treatment and the damage might even be so great as to be career ending.  
 
 
The development of patellar tendon disease can be insidious because the athlete may 
not experience symptoms despite degenerative changes being present, that is, a 
patellar tendon abnormality (PTA) can be seen on ultrasound imaging in a patient 
who is asymptomatic (as will be discussed). Thus, an athlete can have an abnormal 
patellar tendon but not experience any symptoms. Asymptomatic PTA can result in 
the athlete continuing to overload the tendon, which, in Cook & Purdam’s model, 
would drive the health of the tendon along the continuum toward degenerative 
tendinopathy.  
 
Cook & Purdam (2009) state that the suggestions of the model are derived from 
analyzing cross-sectional studies and “supported by findings in animal models”. 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
3 a lesser ability to produce echos compared with neighbouring structures. Appears as varying shades 
of dark grey or black on ultrasound (Silkowski, 2010) 
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They acknowledge that there is limited evidence available from clinical studies. This 
might be what the authors are referring to when they state, “the integrity of the model 
will only be as good as its capacity to withstand additional research”. Furthermore, a 
critique, which is a polemic (Robinson, 2010) and not an empirical piece of work, 
challenges the influence of load as a catalyst. It criticises the “presumption” of 
overload as the key initiating factor and argues that the continuum theory does not 
explain the “large population who develop tendon pain without overload / overuse”. 
The model, which includes both manifestation and management, could be made even 
more useful if terms associated with “load” and “individual factors” were more 
clearly defined. For example, “normal”, “excessive”, “appropriate” and “optimized” 
are terms which lack precision. Overcoming this may increase the clinical utility of 
the model. 
 
Despite these limitations, Cook & Purdam’s model is frequently cited (as discussed) 
as being useful clinically because it appears to capture possible disease trajectories. 
This gives it a measure of face and possibly content validity. It also has utility in 
communicating, to an athlete, the risk of disease progression in the absence of any 
modification in training regimens. In order for this to be successful, however, there is 
a requirement to ensure that an accurate diagnosis of tendinopathy takes place. The 




2.6 Diagnosis of Patellar Tendinopathy 
 
The diagnosis of PT is based primarily on a history of characteristic symptoms 
(activity related, anterior knee pain) and positive clinical examination findings (Cook 
et al., 2001). The diagnosis is then often supported with consistent musculoskeletal 
imaging findings, that is a patellar tendon abnormality (PTA). Each of these 
diagnostic processes is discussed and reviewed below. 
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2.6.1 Clinical Examination 
 
The examination for PT involves palpation of the patellar tendon and it’s bony 
attachments. As the patellar tendon lies immediately beneath the skin, it can be easily 
palpated. Classically, athletes with patellar tendinopathy will experience pain on 
palpation of the inferior pole of the patella and or the proximal patellar tendon 
(Brukner et al., 2007). The examination also includes asking the patient to perform 
functional movements such as squatting, lunging or hopping to load the patellar 
tendon (Brukner et al., 2007; Cook & Purdam, 2009). Such movements aim to 
reproduce the pain of patellar tendinopathy. 
 
 
2.6.2 Musculoskeletal imaging modalities used in the diagnosis of PT 
 
The clinical diagnosis of PT is usually confirmed with musculoskeletal imaging. 
Both ultrasound imaging and Magnetic Resonance Imaging (MRI) are commonly 
used in confirming clinically diagnosed PT (Warden et al., 2007). These have 
advantages over other diagnostic modalities such as Computed Tomography (CT). 
For example, unlike CT scans, ultrasound and MRI modalities do not expose patients 
to potentially harmful radiation. Warden et al., (2007) investigated the comparative 
accuracies of US and MRI in detecting PT by comparing a cohort of 30 patients with 
clinically diagnosed patellar tendinopathy with 33 matched healthy controls (i.e. 
without PT). They found that ultrasound imaging was more accurate than MRI in 
detecting clinically diagnosed patellar tendinopathy (83% vs 70%, P0.04). Grey-
scale ultrasound (GS-US) was found to be the most sensitive (i.e. The proportion of 
people with symptoms of PT who have a positive test result) at detecting patellar 
tendinopathy (sensitivity of 87% vs 57% for MRI, P= 0.01). The specificity (i.e. The 
proportion of people without symptoms of PT who had a negative test result) for 
both US and MRI modalities was 82%. 
 
The authors also used colour doppler ultrasound (CD-US), which is used to examine 
the knee in a different way from grey-scale ultrasound. CD-US reveals blood flow. 
Neoneurovascularisation (the development of new blood vessels and accompanying 
nerves) would be indicative of the healing process, which only occurs as a 
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consequence of damaged tissue. In a longitudinal study over five months in 
volleyball players in Australia, Cook et al. (2005) found that persistent vascularity on 
CD-US was associated with increased pain scores (p=0.043). It is thought that the 
neoneurovascularisation may be responsible for, or at least contribute to, the pain 
experienced in PT (Alfredson et al., 2003). This provides the basis for one of the 
treatment modalities for PT i.e. sclerosing therapy, which eradicates newly 
developed nerve fibers.  
 
In the Warden et al. (2007) study, CD-US had good accuracy as a result of its ability 
to confirm when PT was diagnosed on clinical examination (sensitivity) and its very 
good ability to confirm when clinical examination was negative for PT (specificity). 
Warden et al. conclude that GS-US combined with CD-US may represent the 
imaging approach of choice. GS-US should be used given its good sensitivity (87%), 
while CD-US enhances the diagnostic ability because of its high positive predictive 
value (proportion of those who test positive, who actually have symptoms of PT, 
91%). This makes GS-US coupled with CD-US the gold standard, which explains 
why this imaging modality has been used in the majority of patellar tendon studies. 
 
Ultrasound imaging has further benefits over other radiological investigations, it is 
both time and cost efficient when compared to CT and MRI, especially when 
scanning large numbers of individuals such as those involved in team sports. 
However, providing ultrasound investigation for all athletes, especially those 
involved in team sports, would be prohibitive. It is dependent on having the expertise 
of an ultrasonographer and possibly a radiologist for reporting. In addition, the 
necessary equipment is expensive. Therefore, a method of screening for PT, which in 
the first instance would not require the expertise of medically qualified professionals, 
could be very beneficial. It would allow comprehensive coverage of at risk athletes. 
Those with any indication of PT would be followed up with gold standard 
investigation i.e. GS-US and CD-US. 
 
There would need to be strong justification for comprehensive screening of all 
professional (elite or sub-elite) rugby players even with an easy to perform predictive 
test. The justification is set out below:  
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1. Degenerative changes in the tendon (PTA) can be identified before an athlete 
experiences symptoms thus avoiding further damage to the tendon from 
continued overuse (as discussed above).  
2. The perceived scale of the problem (epidemiology). 
3. The condition can be career limiting (impact). 
 
Epidemiology and impact are dealt with below.	  	  	  	  
2.7 Epidemiology of Patellar Tendinopathy 
 
 
2.7.1 Prevalence in elite athletes 
 
Prevalence is defined as the proportion of a population that suffer from a particular 
disease at a particular moment in time (Dancey et al., 2012). It has been reported that 
patellar tendinopathy has an estimated overall prevalence of approximately 14% in 
general elite sporting populations (Lian et al., 2005; figure 2.3), with an additional 
8% reporting previous symptoms of patellar tendinopathy. In this cross-sectional 
designed study, Lian et al. (2005) used a combination of injury questionnaire and 
clinical examination in elite Norwegian athletes. The estimated prevalence 
corresponds to one in five athletes being affected during their career. 
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Figure 2.3: Prevalence (%) of current (gray bars) and previous (hatched bars) symptoms of jumper’s 
knee. The results for female athletes (F) are shown in the 2 upper bars; the rest of the results are for 
male athletes. Error bars denote SE (Lian et al. 2005). 
 
 
The high prevalence of patellar tendinopathy in elite male volleyball athletes is 
consistent across several studies with rates of approximately 40-50% (Ferretti et al., 
1984; Ferretti et al., 1990; Lian et al., 1996). It is thought that the sports with the 
highest prevalence of patellar tendinopathy are those that are characterised by high 
demands on speed and power of the leg extensors (Lian et al., 2005; Visnes et al., 
2012). They are typically sports, like rugby, that involve jumping, sprinting, and 
cutting. This explains why the sports with the highest reported prevalence are 
basketball, volleyball, athletics and soccer. More recent studies and systematic 
reviews rely on the results of Lian et al. (2005) for prevalence estimations. 
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2.7.2 Prevalence in non-elite athletes 
 
A cross-sectional survey performed by Zwerver et al. (2011), reported that the 
overall prevalence of “jumper’s knee” in non-elite athletes from different sports 
(basketball, volleyball, handball, korfball, soccer, field hockey and track and field) 
was 8.5%. The sport with the highest prevalence was again found to be volleyball 
(prevalence of 14.4%). This is the only study of non-elite athletes reporting 
prevalence across different sports (rugby was not included in this study). There is 
increasing penetration of rugby in the general population through programmes such 
as Rugby Allstars, which is the Welsh Rugby Union scheme that begins at age three. 
This means that the population of non-elite rugby players is increasing. There are no 
reported prevalence estimates for such players. Given the findings by Zwerver et al. 
(2011), this will need to be given due consideration. 
 
 
2.7.3 Prevalence in Rugby 
 
Rugby is devoid of studies into patellar tendinopathy and as such, the prevalence of 
patellar tendinopathy in rugby is not known. Since rugby became a fully professional 
sport in 1995, there have been few large scale epidemiological studies concerning 
injuries. The largest injury surveillance data for rugby injuries comes from the 
Epidemiology of injuries in English professional rugby union studies (Brooks et al., 
2005a; Brooks et al., 2005b)). The studies report only three incidences of PT in 546 
players over two years. This is much lower than the prevalence estimations of PT in 
other sports, which involve similar skills to rugby. The explanation for this may lie in 
Brooks et al. (2005a, p. 757) definition of an injury, which is: 
 
“any injury that prevents a player from taking a full part in all 
training and match play activities typically planned for that day for a 
period of greater than 24 hours from midnight at the end of the day 
the injury was sustained.”  
 
 
This definition has its basis in acute injuries only i.e. those which occur in the match 
or training environment and lead to time off from training or competition. However, 
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from an understanding of the aetiology of the condition, using such a definition may 
well have lead to instances of PT being missed because of its insidious nature. In 
turn, this may result in players not missing training or competition in that 24 hour 
window (for reasons that have already been described). This is also true of 
epidemiology studies into rugby injuries from other countries (Bird et al., 1998; 
Bathgate et al., 2002).  
 
The International Rugby Board (IRB), the governing board for professional rugby, 
started collecting injury surveillance data at the Rugby World Cup (RWC) in 1995. 
They have done this for each of the rugby world cups since. However, only the 
injury surveillance data collected from the 2007 (Fuller et al., 2008) and 2011 (Fuller 
et al., 2012) rugby world cups were consistent with the protocol of the International 
Consensus Statement for Epidemiological Studies in Rugby (Fuller et al., 2007). 
Thus, the pre-2007 data is not reliable and therefore not comparable with post-2007 
data. This means that data exists for two Rugby World Cups only. However, the 
consensus statement for epidemiological studies in rugby has not addressed the 
problem in relation to Brooks et al. studies with regards to chronic overuse injury. 
The consensus statement (Fuller et al., 2007, p. 329) states that an injury is defined 
as: 
 
“Any physical complaint, which was caused by a transfer of energy 
that exceeded the body’s ability to maintain its structural and/or 
functional integrity, that was sustained by a player during a rugby 
match or rugby training, irrespective of the need for medical attention 
or time-loss from rugby activities. An injury that results in a player 
receiving medical attention is referred to as a ‘medical-attention’ 
injury and an injury that results in a player being unable to take a full 
part in future rugby training or match play as a ‘time-loss’ injury.” 
 
 
Once again, using this definition, chronic overuse injuries might be missed and this 
may well be obfuscating the actual prevalence. This is because the condition may be 
characterised by its insidious onset, which may not be connected to a particular 
match or training session. It can also cause confusion because one player could fall 
into both categories. In addition, the problem is compounded because of coding 
issues. As far as can be ascertained from the report, the coders may have classified 
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PT severally as either “knee injuries” or “tendon rupture / tendinopathy / bursitis” 
(not specifying joint affected). The reporting of injury rates in this way is advocated 
in the consensus statement on data collection procedures for studies of injuries in 
rugby union (Fuller et al., 2007). However, as these codes may cover a wide variety 
of pathologies, an accurate estimate to the prevalence of PT cannot be made. In order 
to obtain clarity on coding issues, contact was attempted with the authors of Fuller et 
al. (2012). However, no reply to our communication was received. 
 
Furthermore, the data from the RWC surveillance studies report incidence and not 
prevalence. Incidence is defined as the rate at which injury occurs “during a given 
period in a specified population” (Last, 2000). As patellar tendinopathy is a chronic 
condition, incidence rates over a relatively short period (e.g. 7 weeks in a rugby 
world cup) must be interpreted with caution. Bahr (2009) recognises that the current 
method of surveillance data is inadequate and highlights the need for new approaches 
to quantify overuse injuries in studies.  
 
Increasingly, conversations with rugby sport doctors (and from my own practice) 
suggest that PT is becoming one of the most common chronic injuries presenting to 
health professionals working with rugby athletes. The first aim of this study is to 
investigate the prevalence of patellar tendinopathy in rugby union athletes. It was 
hypothesised that the prevalence of PT in rugby athletes would be similar to, or 
greater than comparable sports i.e. approximately 14%. When this (Giles) study 
began in 2011, useful prevalence data were absent, which is one of the main reasons 
why the study was undertaken. However, In July 2013, Durcan et al. (2013) reported 
on a study of elite academy rugby players in Ireland and reported a prevalence of PT 
of 9.6%. The authors assert that this finding is concerning given that PT is not 
historically associated with rugby. The significance of this finding is discussed in 
relation to both the findings of this thesis and the prevalence reported in the literature 
on sports, other than rugby, which are characterised by high demands on leg extensor 
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2.8 Impact of Patellar Tendinopathy 
 
Athletes with diagnosed patellar tendinopathy may require a prolonged period of 
time away from competition (months to years) while other athletes may never return 
to their full pre-injury level of competition or be forced to retire. For example, 
Kettunen et al. (2002) used the Turku Sports Medicine research unit outpatient 
department database to identify athletes with and without “jumper’s knee”. In the 
fifteen-year follow up, it was discovered that 53% (n=9) of the jumpers knee group 
had reported giving up their sporting career due to knee problems. This compares 
with only 7% of those without jumper’s knee who claimed to have retired from their 
sport due to the knee problem. Although involving small numbers of participants, 
this is the only study located which reports the long-term sequelae of patellar 
tendinopathy. 
 
In part, the impact of PT is inextricably linked to the requirements for managing the 
condition. Current treatment modalities for patellar tendinopathy include rest, 
analgesia, eccentric loading exercises, extracorporeal shock-wave therapy, sclerosing 
or high volume injections, treatment with blood or blood products (to improve 
tendon healing), and surgery (Khan et al., 1998; Zwerver, 2008; Rees et al., 2009; 
Scott et al., 2013). However, the most common treatment for PT is conservative (i.e. 
without surgical intervention). This entails a rehabilitation programme involving 
eccentric exercise and correction of biomechanical risk factors (as will be discussed) 
with the latter not yet subjected to rigorous trials. Even successful treatment may 
require prolonged absences from playing, with Cook et al. (1997, p. 333) reporting 
that among 100 jumper’s knee patients: 
 
“67% of these participants could not play or practice for more than 
four weeks … 34% [of subjects] were unable to play for more than six 
months, with 19% sidelined for more than 12 months”.  
 
 
What is clear is that once acquired, patellar tendinopathy can be difficult to treat 
(Rees et al., 2013) and has serious consequences for both the professional athlete and 
the individual who plays sport for recreational purposes. 
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It follows that the best approach to managing patellar tendinopathy is to avoid its 
development. Van der Worp et al. (2011) argues that because the successful 
treatment of PT remains challenging, prevention is of the utmost importance and 
Finch (2006) notes that knowledge of risk factors is essential in developing 
preventative measures. Two strategies are relevant. The first is to identify risk factors 
and avoid them; the second is to screen athletes (at least the athletes most at risk) 
regularly in order to identify patellar tendon abnormalities as early as possible and 
implement measures to prevent progression. This is particularly important, as a PTA 
(the characteristic ultrasound changes associated with patellar tendinopathy), may be 
present prior to the athlete experiencing symptoms (Cook et al., 2000; Fredberg & 









A Patellar Tendon Abnormality is a patellar tendon ultrasonographic abnormality. It 
is defined as either a hypoechoic region (an area less able to produce echos compared 
with neighbouring structures) seen in both the longitudinal and transverse scans of 
the tendon or a fusiform swelling of the tendon without hypoechoic areas (Cook et 
al., 2000). PTA may be seen in athletes who are asymptomatic. The reported 
prevalence of asymptomatic PTA is variable, ranging from 22-32% (Lian et al., 
1996; Cook et al., 2000, Fredberg & Bolvig, 2002; Gisslèn et al., 2005; Malliaras et 
al., 2006). The significance of this remains uncertain. Studies of PTA seen in 
asymptomatic individuals have shown that there are three possible trajectories for 
untreated PTA: in serial scans PTA may remain unchanged: the PTA improves: or 
the PTA deteriorates (Edwards et al., 2010). Qualitative and quantitative analysis of 
baseline ultrasound images of PTA has been unable to predict which athletes with 
asymptomatic PTA go on to develop symptoms (Cook et al., 2000). Currently there 
is no evidence that predicts which athletes with PTA go on to develop symptomatic 
patellar tendinopathy.  
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Despite this, several papers have suggested that PTA is a risk factor for developing 
symptomatic patellar tendinopathy. For those individuals who have PTA, the 
increased risk of going on to develop symptomatic patellar tendinopathy, is reported 
as 17% in elite soccer players compared with controls (Fredburg et al., 2002). For 
elite junior basketball players, Cook et al. (2000) reported a four-fold increase when 
compared to controls with no PTA. In ballet dancers, the presence of a PTA (on 
Achilles and patellar tendons) was found to be weakly predictive (p=0.0381) for 
future disabling symptoms of tendon disease (Comin et al., 2013). Based on a review 
of a number of empirical studies, Edwards et al. (2010), argued that individuals with 
a PTA demonstrable on ultrasound imaging, are less able to adapt patellar tendon 
load to stresses such as muscle fatigue and are therefore at increased risk of 
developing symptomatic patellar tendinopathy. Cook and Purdam (2009) argue that 
the loss of tendon structure (which leads to the PTA) results in a tendon that is less 
capable of sustaining repeated tensile load. 
 
Furthermore, Edwards et al. (2010) argue that, “It remains unknown, however, 
whether the presence of PTA in asymptomatic athletes affects their landing 
technique or whether their landing technique might predispose them to developing a 
PTA and/or patellar tendinopathy”. It is important that this potential link is 
investigated but it outside the scope of this thesis and should be the subject of a 
follow up study. 
 
 
2.9.2 Anthropometric risk factors 
 
A major contribution to the literature on risk factors for PT has been provided by 
Van der Worp et al. (2011) who undertook the only systematic review, which could 
be located, into risk factors for patellar tendinopathy. As part of the systematic 
review, 683 relevant papers; which met the inclusion criteria; were located after the 
initial search. Following a sift of duplicates, 478 papers survived. The inclusion 
criteria required that studies were empirical research that investigated factors 
associated with PT. Each study required an experimental group and group of 
controls. Only ten of the 478 studies met this inclusion criteria and were included in 
their systematic review.  
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It is noteworthy that only ten of the original 683 studies survived the quality testing 
for level of evidence. It is of note that no other systematic reviews and no 
randomised controlled trials  (RCT) were found. In medicine, the RCT is placed near 
the top of the hierarchy of evidence. Most systematic reviews of clinical conditions 
would only include evidence garnered from an RCT. In the absence of RCTs, cohort 
studies and case-control studies produce results in the next level of the hierarchy of 
evidence. Out of the ten studies that were included, there were six cross-sectional, 
three case-control studies and one prospective cohort study. One of the studies 
reported had two distinct parts producing two sets of results making the number of 
studies that were included 11. The attrition rate from those papers that had the 
potential to be included in the systematic review was 98.5% or 97.9% depending on 
whether the starting figure is 683 or 478.  
 
Out of the 11 studies included in the review, eight investigated whether weight is a 
risk factor for developing PT. This is because theoretically a higher body mass leads 
to higher loading of the patellar tendon. Three of these eight studies showed an 
association between weight (or mass) and PT (Lian et al., 2003 who studied males 
only, P=0.05; Malliaras et al., 2007, p<0.01; Crossley et al., 2007 whose studies 
included males and females, p<0.02). The first two of these studies exclusively 
involved volleyball players, whereas the third, Crossley et al., investigated athletes 
from varying sports such as volleyball, basketball, netball, soccer and tennis. As well 
as weight, Crossley et al. (2007) also demonstrated an association between body 
mass index (BMI) and patella tendinopathy. This was the case for both unilateral and 
bilateral patellar tendinopathy. This finding was similar to that of Malliaras et al. in 
2003. Of the six studies included in the systematic review that looked at height, no 
study found an association between height and patellar tendinopathy (Lian et al., 
1996; Witvrouw et al., 2001; Lian et al., 2003; Cook et al., 2004; Gaida et al., 2004; 
Malliaras et al., 2007). This suggests that the key variable may be weight. For this 
thesis, it was anticipated that the participants with patellar tendon disease would have 
a higher body mass than those participants with healthy patellar tendons. 
 
In addition to weight, other anthropometric characteristics were studied. These 
include: BMI (because weight is one of the variables used to calculate BMI), waist-
to-hip ratio, leg length difference, arch height of foot, quadriceps flexibility, 
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hamstring flexibility, quadriceps strength and vertical jump performance. However, 
the evidence for these risk factors being associated with PT was not strong and the 
authors argue that further studies are required before any conclusions could be made. 
 
 
2.9.3 Playing position 
 
Given that the relationship between position and PT in rugby players has not been 
studied, even in the recent Durcan et al. (2013) study, it follows that the risk factors 
of various rugby playing positions has not been studied either. Rugby athletes share 
skills that are common to athletes of other sports, which have a high prevalence of 
patellar tendinopathy. These include running, jumping and cutting. However, 
different positions within a rugby team would engage in different frequencies of 
these skills e.g. second row forwards being more likely to be involved in line-outs 
(Sankey et al., 2008); which often result in landing from six feet or more, and 
scrummaging, whereas the backs would traditionally be involved in more sprinting 
and cutting activities (Eaton & George, 2006). Forwards have also been shown to be 
generally taller and heavier than backs (Fuller et al., 2012). 
 
A study by Lian et al. (2003) into patellar tendinopathy in elite male volleyball 
athletes found that there was a significant difference in the prevalence of PT 
according to the position played. They found that the prevalence of PT in outside 
hitters and middle blockers was significantly higher than utility blockers and setters. 
The authors argued that this could be explained by the higher number of maximal 
jumps performed by outside hitters and blockers than by other positions. As no data 
currently exists for rugby athletes, it is unclear whether the prevalence of patellar 
tendon disease differs according to playing position as it does in volleyball athletes. 
Therefore it seemed logical that another of the aims of this (Giles) study was to 
examine whether there is a relationship between player position and the presence of 
patellar tendon disease in rugby. It was anticipated that patellar tendon disease would 
be more prevalent in rugby forwards as these athletes are more likely to engage in 
maximal jumping activities (e.g. line outs) and are likely to have a greater body 
mass. The possible relationship between anthropometric risk factors and the 
prevalence of PT in rugby, for which there is little strong evidence, informed the 
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study design of this thesis. 
 
 
2.9.4 Ground Reaction Forces 
 
The first strategy in managing PT, that is identifying risk factors, has proven to be 
problematic. This is because the evidence is either weak, equivocal or absent. 
Turning now, to the second strategy, that of serial screening remains. As already 
discussed, the gold standard of screening, i.e. to ultrasound scan everyone, has 
drawbacks such as the expense and expertise required. What would be really helpful 
would be to identify a screening method that was simple to use, did not necessarily 
require qualified healthcare professional expertise and that could predict the presence 
of patellar tendon disease. Such a screening method may involve force plate analysis 
of landing activities. Force plates measure and record ground reaction forces (GRF). 
The action of a force (e.g. a rugby player’s weight) on the ground receives an equal 
and opposite reaction force, this is the GRF (Porter, 2008). 
 
It has been reported that athletes with patellar tendinopathy have altered lower limb 
landing strategies when compared to healthy controls (Richards et al., 2002; 
Bisseling et al., 2007). It is hypothesised that it is an increased patellar tendon load, 
and the inability to adapt to this increased patellar tendon strain, which predisposes 
to patellar tendinopathy.  
 
Seegmiller & McCaw (2003) cite Sands et al. (1993) and report that the most 
prevalent type of lower limb injury in gymnasts is “repetitive stress syndrome 
injuries”. To investigate whether the landing strategy of healthy gymnasts differed to 
that of healthy recreational athletes (and possibly predisposing to these injuries), 
Seegmiller and McCaw (2003) measured peak vertical ground reaction force 
(VGRF) and loading rate (LR) VGRF during a drop-landing protocol. The drop-
landing protocol involved stepping off pre-determined heights of 30-, 60-, and 90-
cm. The authors report that the gymnasts exhibited a 33% and 34% increase in 
VGRF, compared to non-gymnasts, when landing from a height of 60 cm and 90 cm 
respectively. There was no difference in the LR VGRF between the two groups of 
participants. The authors argue that the repetitive exposure to high loads during 
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landing may contribute to injury. Furthermore, Fietzer et al. (2012) described that 
dancers with patellar tendinopathy exhibited 36% greater peak VGRF during landing 
tasks when compared to their healthy counterparts. This notion concurred with 
Richards et al. (2002) who suggested that a high VGRF during landing tasks in 
indoor volleyball athletes might serve as a predictor of patellar tendinopathy.  
 
In contrast, Bisseling et al. (2007) performed drop-jumps on 24 volleyball athletes 
from three different heights (30 cm, 50 cm and 70 cm). They found that there was no 
difference in the peak VGRF between athletes who had previous (but now 
asymptomatic) PT, recent patellar tendinopathy or healthy controls. In this study, 
Bisseling et al. used a clinical diagnosis of patellar tendinopathy and did not use 
imaging to confirm diagnosis. However, previous work by Cook et al. (2001) has 
suggested that a diagnosis of PT on clinical grounds alone is unreliable. Although 
there was no difference observed in peak VGRF in the Bisseling et al. (2007) study, 
the authors did observe a higher LR VGRF in the group who suffered previous 
jumper’s knee (p=0.05) compared to controls. This led the authors to conclude that 
patients with previous jumper’s knee used a stiffer landing strategy than healthy 
controls. This stiffer landing may be a risk factor in the development of patellar 
tendinopathy. These findings are similar to those reported by Edwards et al. (2010). 
Edwards and colleagues performed a stop-jump task on seven athletes with a PTA 
demonstrable on ultrasound (but no history or clinical signs of patellar tendon 
disease). These athletes were matched with seven healthy controls. The stop-jump 
task involved both a horizontal and a vertical landing phase. The authors found no 
significant between-group difference in the peak VGRF or the LR VGRF for the 
horizontal landing phase of the stop-jump task. However, during the vertical landing 
phase, the group with the PTA demonstrated a significantly lower LR VGRF 
compared with the control group (P = 0.03). There was no significance between 
groups for peak VGRF. 
 
It is not clear whether differences in VGRF may pre-dispose to patellar tendon 
disease or be the product of adaptive changes in landing strategy as a result of the 
disease (Bisseling et al., 2007). Although the evidence remains equivocal in that one 
study has been identified which found peak VGRF would not be useful in identifying 
athletes suffering from, or at risk of patellar tendon disease, there is more evidence 
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that it may be useful in this regard. If VGRF from landing tasks were found to be a 
valid method of screening for patellar tendon disease in rugby, this efficient and 
easy-to-use test could identify those with patellar tendon disease, or those at risk. 
This would enable appropriate management of the condition so preventing the 
requirement to take prolonged time off from competition or even early retirement. 
Therefore, the final aim of the study was to begin to investigate whether players with 
patellar tendon disease (symptomatic or asymptomatic) exhibited different VGRF 
and LR VGRF than controls and whether logistic regression could predict tendon 
status in rugby athletes i.e. whether there is patellar tendon disease or not (regardless 
of symptoms). Were this possible, identifying players with asymptomatic patellar 
tendon disease would allow suitable preventative measures to be put in place before 




2.9.5 Previous injuries 
 
To date, there appears to be no studies suggesting that previous injury to the knee 
may be a risk factor for development of PT. Empirical studies of risk factors for PT 






Although it is accepted that the aetiology of tendinopathy is likely multifactorial, 
recent studies have suggested that genetics may play a role in predisposing 
individuals to the development of tendinopathy. Several studies have investigated the 
association between the ABO blood groups and tendinopathy. However, the 
association between blood group O and rupture of the Achilles tendon (P = 0.03) is 
stronger than for blood group O and chronic tendinopathy (P = 0.1; Kujala et al., 
1992). These results support those found in 1989 by Jozsa et al. in a population 832 
patients with tendon rupture. Conversely, these results have not been replicated in 
more recent studies (Leppilahti, Puranen & Orava, 1996; Maffulli et al., 2000).  
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A review in 2007 (September, Schwellnus & Collins) summarizes the current 
evidence for a genetic component to the development of tendinopathy. This evidence 
mainly involves two genes, Tenascin-C (TNC; Mokone et al., 2005) and COL5A1 
(Mokone et al., 2006). These original studies involved Caucasian athletes 
(individuals with Achilles tendon injuries and a control cohort) from a South African 
population. The findings have since been replicated in an Australian Caucasian 
population with similar results (September et al., 2009). September, Schwellnus & 
Collins (2007) propose that screening for variants in these genes (TNC and 
COL5A1) may have a role in identifying those individuals at risk of developing 
tendinopathy. However, the authors acknowledge that more research is needed 






In conclusion, PT is a common condition among sporting populations and is thought 
to be mainly degenerative in nature. According to Cook and Purdam (2009), there 
are three stages: reactive tendinopathy, tendon dysrepair and degenerative 
tendinopathy. Whilst recovery from reactive tendinopathy is possible with 
appropriate management, this becomes more difficult with tendon dysrepair and 
limited when the stage of degenerative tendinopathy is reached. The consequences 
for an athlete who is not appropriately managed can be career limiting or even career 
ending. The development of the condition can be insidious and difficult to link to any 
particular match or training episode. Furthermore, patellar tendon disease may be 
present in the absence of symptoms. However, it has been demonstrated that athletes 
who have asymptomatic patellar tendon disease are at increased risk of developing 
future disabling symptoms of patellar tendinopathy. 
 
There are several studies of PT in sports that involve similar skills to rugby. Whereas 
prevalence rates vary, there is sufficient evidence that PT is a recognised 
consequence of playing these sports. Very few studies investigating the prevalence of 
PT in rugby exist which was one of the reasons for this (Giles) study. Those studies 
that do exist are problematic for several reasons. The definition of PT used in studies 
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has led to under-reporting of the condition. There is a lack of consistency as to 
whether incidence or prevalence is reported (incidence is not recommended for 
chronic overuse injuries) and problems with coding have resulted in ambiguity. A 
recent study (2013) by Durcan et al. (reported after this thesis began) demonstrated a 
high prevalence of patellar tendon disease in academy rugby players. Other 
prevalence studies in rugby have significant flaws in the methodology so the results 
cannot be relied upon.  
 
Patellar tendinopathy is a condition that is frequently written about. However, when 
undertaking a systematic review, Van der Worp et al. (2011) found only eleven 
studies which met their inclusion criteria. None of these studies included rugby 
athletes. The conclusion of the systematic review was that there was not a strong 
relationship between various anthropometric characteristics and PT, apart from 
weight for which there was a reasonably strong association. In team sports other than 
rugby, an association between PT and playing position has been demonstrated. The 
methodology for this (Giles) study was designed to begin to address the lack of data 
on these relationships for rugby. It was hoped that the risks to rugby players of 
developing patellar tendinopathy could be better understood.  
 
There is an accepted gold standard for diagnosing patellar tendon disease. This 
includes clinical examination accompanied by ultrasound imaging of the patellar 
tendon. The difficulties associated with providing both tests on a comprehensive and 
regular basis have been described. There is some evidence from other sports that 
altered VGRF measurements from landing tasks would be a proxy measure for the 
presence of PT. Drop-landing tasks are easy to perform and if the VGRF 
measurement was predictive of patellar tendon disease in rugby, it would allow 
comprehensive and regular screening of rugby athletes. In turn, this could lead to 
appropriate management, prevention of further degeneration and preservation of the 
athlete’s career. The study design therefore included an investigation of whether 
force plate analysis of drop-landing tasks could predict the presence of patellar 
tendon disease. 
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The study design is informed by the conclusions of the literature review (chapter 2), 
the researcher’s personal experience as a medical officer to a rugby club, and 
personal communication with other sports doctor colleagues about the prevalence of 
patellar tendon disease in rugby: the relationship between patellar tendinopathy and 
various risk factors, and the extent to which the presence of patellar tendon disease 
can be predicted using analysis of ground reaction forces. In order to address these 





3.2 Aims and Objectives of the study  
 
Prevalence 
To estimate the prevalence of patellar tendon disease in rugby players, the following 
objectives were set: 
1. To determine the prevalence of symptomatic patellar tendinopathy (PT) in a 
sample of rugby union athletes 
2. To determine the prevalence of asymptomatic patella tendon disease seen on 
ultrasound imaging in a sample of rugby union athletes. 
 
Patellar tendon disease and risk factors 
In order to understand the relationship, if any exists, between patellar tendon disease 
and anthropometric factors and playing position, the following objectives were set: 
3. To investigate whether rugby athletes with patellar tendon disease have a 
greater mass than rugby athletes with healthy tendons. 
4. To investigate whether playing position affects the prevalence of patellar 
tendon disease 
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Prediction of patellar tendon disease 
In order to investigate whether it is possible to predict the presence of patellar tendon 
disease using force plates, therefore avoiding the need for ultrasound screening of 
high numbers of athletes, the following objectives were set: 
5. To investigate whether rugby athletes with patellar tendon disease have 
different vertical ground reaction forces when performing drop-landing tasks 
than controls 
6. To investigate whether force plates measuring vertical ground reaction forces 
from drop-landing tasks can predict tendon status during a landing task i.e. 




3.3 Study Design 
 
To deliver the study’s aims and objectives, a multi-method approach was considered 
necessary. The design of the study entailed the following:  
 
1. Recruitment of a sample of rugby players 
2. Collection of data on each study participant’s general characteristics 
3. Collection of baseline symptom score on each study participant’s 
4. Examination of study participants, clinically and with ultrasound, for signs of 
patellar tendon disease 
5. Performing a drop-landing task to measure vertical ground reaction force 
(VGRF) and Loading rate VGRF (LR VGRF) 
6. Undertaking statistical analysis to: 
a. Estimate the prevalence of patellar tendon disease 
b. Examine the relationship, if any exists, between patellar tendon status 
and weight and playing position 
c. Examine the relationship, if any exists, between patellar tendon status 
and VGRF and LR VGRF  
7. In order to be able to undertake data analysis, it was necessary to categorize 
participants into one of the following groups: 
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a. Asymptomatic; no ultrasound changes (the control group) 
b. Asymptomatic; positive ultrasound changes (comparison group 1, 
hereafter named “PTA group”) 
c. Symptomatic (comparison group 2, hereafter named “PT group”) 
 




3.4 Ethical Approval 
 
As the research involved human subjects, ethical approval was sought from the 
University Research Ethics Committee. The main ethical considerations were: 
 
That participants would be assured of anonymity and confidentiality. That is, that 
none of their personal data or individual findings would be disclosed to a third party 
without the participant’s expressed consent. Each participant was given a unique 
identifier (known only to the researcher), which was stored separately from the 
participant’s name. This meant that it was not possible to identify any player by the 
results.  
 
That all data were stored on a password protected file. Only the research team knew 
the password to this file. This allowed for adequate protection of information whilst 
also enabling verification of findings (if needed). 
 
That each participant would give informed consent to be involved in the study. This 
means that the study’s aims and objectives, and data collection and handling 
processes would be explained to the participant in terms that they could understand. 
It also meant that participants would be given an opportunity to ask questions for 
clarification on any point. As part of informed consent also, each participant would 
be informed that they could withdraw from the study at any time and request that any 
of their personal data be destroyed. In addition, they would be informed that no third 
	   31	  
party would be informed of their withdrawal. 
 
That any discovery of PT previously undiagnosed would be handled appropriately. 
This meant that at an appropriate time participants would be informed of the findings 
and advised of the diagnosis and that this should be shared with the coaching / health 
professional team so that appropriate management could be instigated. However, it 
was made clear that the decision to do this would rest with the participant. 
 
An information leaflet (appendix 3) was devised which set out all of the above 
details and was provided to each participant. Before any data were collected, an 
informed consent form (appendix 4) was signed. These issues were addressed in this 
way in order to comply with relevant legislation e.g. Data protection act 2008 and 
sound ethical principles on conducting human research as set out in the current 






If the hypothesis that there is a high prevalence of patellar tendon disease in rugby 
players was correct, then it was anticipated that the data would fall in to two groups. 
The first group would have healthy patellar tendons and the second group would 
have patellar tendon disease (this second group could be further subdivided into 
those who had clinical signs of the disease, and those who were clinically silent). The 
differences between the two main groups, in terms of a number of variables (mass, 
playing position etc.), would then be analysed. In doing this, it would be important to 
analyse the size of the difference between the two groups. For this study, this would 
include understanding the level at which the difference in mass affected tendon status 
and what effect size in VGRF would be indicative of the presence of tendon disease. 
When this study commenced, there were no published studies in rugby which have 
examined the relationship between these variables and patellar tendon disease, it 
meant that there was not any data regarding distribution, standard deviation etc. of 
these variables in rugby players with patellar tendon disease. The absence of these 
data would make it very difficult, if not impossible, to state likely effect size in 
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VGRF due to disease. For this reason, it was felt that it was not appropriate to 
undertake power analysis to determine the sample size needed to examine the 
differences between the two groups.  
 
It was, however, hoped that this study would provide sufficient data for future 
studies about prevalence (as noted above), and the distribution (including standard 
deviations) of all the key variables, and in particular what difference in effect size 
could be anticipated between a group of healthy players and those with patellar 
tendon disease. In turn, this would enable power calculations to be undertaken for 
future studies. It might be that any differences that would be material would be 
subtle, and if this were to be the case, a large sample size would be required. 
However, at the start of this study, there was no robust data about prevalence of 
patellar tendon disease in rugby athletes. It would be unethical to subject a large 
number of players to testing (even though testing would be non-invasive) when the 
presence or absence of the key variable was not known, i.e. was patellar tendon 
disease prevalent or not? 
 
It was decided that age-grade players (those still eligible to play for an under-20 
team) would be targeted for inclusion in the study: Access was more straightforward 
as the season was already underway during the data collection period and it was 
considered that age-grade rugby players would have less playing, training and 
sponsorship commitments than senior players. As is discussed fully in chapter 5, it 
transpired that age-grade players might have greater training commitments than the 
senior squad, which causes problems when extrapolating results from the sample to 
the senior squad. In addition, at this stage there was no certainty of the prevalence of 
patellar tendon disease or that a relationship between VGRF and PT existed (a proof 
of concept had yet to be established). Depending on the findings, the study could be 
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3.6 Inclusion / Exclusion Criteria 
 
1. All participants had to be free from any acute back or lower limb injury (not 
including patellar tendinopathy) i.e. each study participant had to be 
undertaking a full competitive training regime as advocated by Bisseling et 
al. (2007) who report that any acute injury may affect biomechanical 
properties of movement tasks and have a confounding effect on results. In 
addition, the inclusion of players with back or lower limb injury might 
expose the player to unnecessary risk (this is discussed in more detail in 
ethical considerations). At any one time, approximately 25% of rugby squads 
are injured (Holley, 2010), which reduces the total possible sample size. 
 
2. All study participants had to have been playing competitive rugby for at least 
5 years prior to enrolment in to the study. This was to ensure that study 
participants were established rugby athletes and had experienced the typical 
physical stresses of rugby matches and training practices. The literature is 
silent on the length of playing time required for sample selection that would 
represent a typical rugby population (it transpired that none of the athletes 
included in the study had played elite rugby for less than 5 years).  
 
3. Only those players aged 18 years and over at the time of recruitment were 
offered the opportunity to participate, i.e. a player of exceptional ability who 
at 17 years of age may be representing an under 20 squad was not invited to 
participate. It would have compromised the study to include players under the 
age of 18 (even if they were representing an under 20 squad and had played 
competitive rugby for five years) because of the risk that the player may have 
had Osgood–Schlatter and/or Sinding-Larsen-Johansson syndrome which 
occurs in the adolescent athlete. Both these conditions result in symptoms 
that affect the extensor mechanism of the knee (Brukner et al., 2007) and can 
mimic patellar tendinopathy. Exclusion of participants based on the 
possibility of these conditions being present is also advocated by Malliaras et 
al. (2007). Informed consent and other safeguarding procedures were more 
straightforward for individuals over the age of 18 years of age. 
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The total population of under-20 elite players in Wales is circa 80. This compares 
with Ireland, another UK country with the same number of regions (four) as Wales 
(Durcan et al., 2013). It was decided, therefore, that the drawn sample would be all 
regional academy players in Wales under-20 years of age (but over the age of 18 
years).  Given that the estimation that 25% of players in a squad are injured at any 
one time, this probably means that the potential total sample size is circa 60 players. 
Nevertheless, because 25% is an estimate, 80 was taken as the total possible sample 




3.7 Recruitment Strategy 
 
Following approval for the study from University’s Human Research Ethics 
committee, contact was made with each of the four regional rugby clubs in Wales 
inviting their age appropriate under-20 academy athletes to participate. Initial contact 
was made via an information letter (or email) distributed to coaching and/or medical 
staff at the respective rugby club (appendix 2). The letter contained the study’s 
details and a statement seeking permission to invite their athletes to take part. Once 
permission from the club representative was granted, visits were made to each region 
to discuss the opportunity with the coaches and the potential players involved. 
Recruitment letters and information leaflets (appendix 3), which were approved by 
the University Ethics Committee, were offered to potential participants. Where visits 
could not be arranged in a timely manner, dialogue took place via telephone 
conversation and/or email. Formal invitations to participate in the study were made 
to the players directly. As initial response was poor, it was decided that we would 
request the club physiotherapists to invite the participants into the study. Contact 
information was offered so that any player (and/or coach) could seek further 
information. 
 
Before participation within any part of the study commenced, each participant had 
completed and returned written informed consent using consent forms approved by 
the University Ethics Committee (appendix 4).  
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3.8 Baseline demographic data 
 
The demographic data collected were limited to that which was necessary to meet the 
study objectives. Numbers of players per region are available (see results section). 
However, cross-tabulation by region was not undertaken for several reasons: 
1. The sample size per region was too small to provide meaningful results 
2. The results would not have informed the study objectives 
3. An undertaking of confidentiality was given to players and the regions. 
Presenting data by region would breach confidentiality and might have 
commercial consequences for the region. Furthermore, breach of 
confidentiality could result in resistance to participation in future research. 
However, individual reasons were given their results. 
 
Data on the player’s age, stature, weight, favoured playing position and dominant 
foot for kicking were collected. Stature was measured with the athlete barefoot using 
a standard stadiometer and recorded to the nearest centimeter. Body mass was 
measured using a commercially available force plate (400 Hz: Accupower Plate; 
Amti Advanced Mechanical Technology Inc., MA, USA) connected to a computer. 
During measurement, the force plate was zeroed, and the participant instructed to 
step on to the force plate, to stand upright in the centre of the force plate and to face 
forward. The weight of the participant was recorded in kilograms (rounded to one 
decimal place e.g. 96.7kg). 
 
Study participants were asked their favoured playing position and their dominant 
foot. Favoured playing position was defined as the position on the rugby field where 
they played the majority of their competitive rugby games. Dominant foot was 
defined as the foot they would use if they wanted to kick a rugby ball the greatest 
distance. Study participants were asked to reveal whether they had ever had a 
previous diagnosis of patellar tendinopathy or “jumper’s knee”. This question was 
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3.9 Baseline symptom score (for use as a clinical management tool if PT or PTA 
was diagnosed)  
 
One of the key ethical considerations (which are discussed in detail below) was what 
to do if PT was diagnosed during the study. It would be unethical not to offer the 
player referral for appropriate treatment and further investigations by the health 
professionals in the player’s region. The only questionnaire widely used to assess the 
symptoms of diagnosed patellar tendinopathy is the VISA-P score. The VISA-P 
score (appendix 5) would provide the baseline from which the player’s own regional 
health professionals could monitor the effect of subsequent treatment. It was devised 
by the Victorian Institute of Sport in Melbourne with the primary aim of assessing 
the severity of symptoms and functional status of those patients with patellar 
tendinopathy (Visentini et al., 1998). It is a self-administered questionnaire that is 
widely used to monitor response to treatment in established patellar tendinopathy. It 
has been shown to be a reliable and a valid tool for determining whether athletes 
experience symptoms from their already diagnosed patellar tendinopathy (Khan et 
al., 1999; Cook et al., 2000). This was important so that we could be confident in the 
content of any referral made. The VISA-P has benefits over other scoring systems 
(such as the Cincinnati Sports Activity Score or Visual Analogue Scales) as it was 
specifically designed to assess functional status for those with patellar tendinopathy 
and not lower limb injuries in general. 
 
VISA-P is not intended as a research tool but as a clinical tool to assess progress of 
management following diagnosis. The VISA-P questionnaire is one intended for 
players to complete. That is self-report. There is always a risk in any self-reporting 
tool that respondents will “fake good” (Streiner and Norman, 2000) or provide what 
is perceived to be “socially desired responses”. For example, the cause of faking 
good might be to avoid missing training or playing (and potentially incurring 
financial loss). In the case of socially desired response, the player may not wish to let 
down either his team mates or coaching staff: or perceive the symptoms to be a sign 
of weakness within a highly competitive environment. This means that there is a risk 
of obtaining false negatives if the VISA-P was used as a screening tool for patellar 
tendon disease. For these reasons there is a risk of using a self-reporting tool of this 
kind for research purposes. A reliable and valid research tool is designed in such a 
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way that such potential biases could not influence the responses given.  
 
The VISA-P scores form part of the ethical integrity of the study i.e. they could be 
used to provide a symptom baseline for further management. It was initially decided 
not to use the VISA-P questionnaire as a screening tool. The total possible VISA-P 
score is 100. Points are deducted according to symptoms identified. To be used as a 
screening tool, it would be essential to know at what VISA-P score a player should 
be referred for clinical examination and ultrasound screening of their patellar 
tendons. This would entail very detailed scaling work to attempt to identify a 
threshold for referral and, in any event, such an outcome may never prove possible 
because VISA-P is designed as a tool for use with those who already have 
symptoms. If it were possible to identify a threshold, the issue of faking good would 
undermine the tools usefulness. Having said that, this hypothesis was tested by 
undertaking a cross tabulation of VISA-P scores with the presence or absence of 
disease. 
 
It was decided that the researcher would assist the players in completing the VISA-P 
questionnaire. This would ensure a higher response rate than would be the case if the 
questionnaire were given with the request that it be returned by post. This approach 
would also ameliorate the difficulties associated with any potential poor literacy 
levels. Again the rationale for taking such care over this issue was to ensure that any 
clinical condition did not deteriorate because it had not been drawn to the attention of 
both the player and their health professionals.  
 
 
3.10 Clinical Examination 
 
Each player (n=46) received an assessment by an experienced sports medicine 
physician (appendix 6) who had no knowledge of their previous medical history or 
the symptoms that may have been recorded on the players VISA-P score. The 
clinician asked simple questions about pain and tenderness experienced during 
examination. The clinician did not ask questions concerning pain and tenderness 
experienced during training and competition. This meant that players were 
categorised according to clinical findings only. 
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The examination for each player followed a standard protocol with specific focus on 
looking for signs of patellar tendinopathy i.e. pain to palpation over the inferior pole 
of the patella and pain at the insertion of the patellar tendon when performing 
functional exercises. This ensured an element of consistency. Following the approach 
advocated by Brukner et al. (2007), the clinical examination started with the 
participant standing with legs adequately exposed. The participants were asked to 
undergo functional exercises, which involved loading the extensor mechanism of the 
knee to try to reproduce the pain associated with patellar tendinopathy. These 
included hopping on one foot, lunges, squatting and single leg squatting (figure 3.1). 
A total of 10 repetitions for each exercise were performed i.e. ten repetitions for each 


















Figure 3.1: Study participant undergoing lunges 
  
 
Examination continued with the participant lying supine on an examination couch. In 
this position the clinician palpated for tenderness over the inferior pole of the patella 
and at the insertion of the patellar tendon. This was performed both in full extension 
and with the knee in slight flexion (approximately 20 degrees; figure 3.2). Palpation 
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of the patellar tendon is highly sensitive at reproducing the pain of patellar 
















Figure 3.2: Examiner testing for tenderness over the insertion of the patellar tendon 
 
 
It is essential that the data collected on clinical examination was consistent. As there 
was only one examining clinician, there was no need for inter-rater reliability 
analysis. A pro-forma was used by the examining clinician to record whether there 
was tenderness on palpation of the patellar tendon or it’s attachments and whether 
the athlete experienced pain on functional testing. Some researchers (Cook et al., 
2001) have assessed pain by severity using points on an analogue scale. It was 
decided that such an approach was not relevant for this (Giles) study because a. pain 
symptoms had been recorded using the VISA-P score, b. the sample size was too 
small to have safe calculations of cross-tabulations of grades of pain, c. each athlete 
would receive an ultrasound scan as part of the data collection procedure. 
 
The pro-forma used by the examining clinician in this study can be found in 
appendix 7. The final item on the pro-forma required the examining clinician to 
record the presence or absence of clinical findings i.e. a binary choice. This forced 
the clinician to make a firm commitment about their clinical impression and it 
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avoided the need for post-hoc coding of clinical narrative. The format also facilitated 
data entry.  
 
 
3.11 Ultrasound imaging 
 
In the hands of an experienced clinician, ultrasound allows visualisation of the 
patellar tendon and this together with the clinical examination determines with a very 
high degree of accuracy whether tendinopathy is present. As ultrasound is currently 
the gold standard in diagnostic imaging of patellar tendinopathy (Warden et al., 
2007), no testing of validity and reliability was needed on this data collection tool. It 
also has the benefit over other types of diagnostic imaging (e.g. CT scanning) 
because it does not expose the participant to any ionising radiation.  
 
All participants (n=46) received an ultrasound scan of their patellar tendons. Both 
left and right-sided tendons were scanned on each participant. All ultrasound scans 
were performed by the same examiner, who was experienced in the field of 
musculoskeletal ultrasound and uses the technique regularly in orthopaedic clinics 
and in his role as a sports physician to a Welsh rugby region (appendix 6). Again, 
using one clinician to perform the ultrasound scans has the advantage of avoiding the 
need for inter-rater reliability testing. The drop-landing task was performed after the 
ultrasound examination. This approach was to ensure an element of blinding to the 
examiner performing the ultrasound scans, i.e. the examiner would not know the 
result of the drop-landing tasks prior to performing the ultrasound scan and could not 
be influenced by the results. 
 
Ultrasound data were recorded using high-resolution grey-scale ultrasound (256 grey 
shades) with the aid of colour power doppler (256 colours) and a 7 MHz linear array 
transducer (Sonosite MicroMaxx, Washington, USA). For image optimization, the 
focal depth was adjusted to correspond with the level of the patellar tendon. For 
colour power doppler, flow sensitivity was set to “medium”. The scans were viewed 
on the 21.34 cm x 16 cm display. Contrast and brightness settings on the display 
were adjusted corresponding to room conditions to allow clear visualisation of the 
image.  
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In preparation for the ultrasound scan, each player lay at an angle of 45 degrees on 
an examination couch with both limbs adequately exposed (see figure 3.3). This 
allowed an adequate position for imaging of the tendon and also the optimum 
comfort of the participant. During examination, a pillow was placed under the knee 
of the tendon being scanned. This placed the tendon under a slight degree of tension 
and allowed for clearer visualisation (as advocated in Warden et al., 2007). Water-
soluble gel (Aqua-gel) was applied to both the transducer and over the region of the 
patellar tendon. This was to aid diagnostic coupling by removing direct contact with 














Figure 3.3: Position of the participant for ultrasound scanning of the patellar tendon 
 
 
Transverse and longitudinal scans of the patellar tendon were performed. Figures 3.4 
and 3.5 demonstrate the orientation of the transducer used to capture the longitudinal 















Figure 3.4: Orientation of the ultrasound transducer to visualise the tendon belly in the transverse 
plane 











Figure 3.5: Orientation of the ultrasound transducer to visualise the tendon in the longitudinal plane 
 
 
The aim of the ultrasound examination was to identify a PTA. A PTA was defined as 
the presence of a hypoechoic area seen in both the longitudinal and transverse scans. 
An example of a PTA can be seen in Figures 3.4 and 3.5. This definition is consistent 
with that used in other studies (Cook et al., 2000; Cook et al., 2004; Gisslèn et al., 
2007 and Warden et al., 2007). The question of grading the ultrasound changes was 
considered. Cook et al. (2000) concluded that the size of a PTA had not yet been 
shown to correlate with disease or symptom severity. In 2013, in a study of both 
Achilles and patellar tendons, Comin et al. reported that moderate or severe 
hypoechoic areas are weakly predictive only for future symptoms of tendinopathy. 
Moderate or severe were not defined in their paper. This would suggest that at the 
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moment, presence or absence of a PTA should be the only criterion used to classify 
the presence of disease. Even though, Archambault et al. (1998) advocated a grading 
system containing three points (1=normal, 2=tendon thickening, 3=hypoechoic area, 
regardless of size), Comin et al. (2013) found no correlation between any 
sonographic abnormalities (including tendon thickening) and the development of 
symptoms, apart from the presence of hypoechoic areas. For this thesis, it was 
decided that tendons would be considered abnormal (show signs of tendinopathy) if a 
PTA was present (regardless of size). The rationale for this is that any further 
granularity has not been shown to be of material value in either diagnosis, disease 
trajectory or symptom control. 
 
It was decided that the options available to the examiner were binary, i.e. whether 
there was a hypoechoic area or not. This ensured that data collection was as objective 
as possible and that the examiner made a commitment to their diagnosis. This also 
facilitated coding. All tendons in this study considered to have a PTA, had clear 
hypoechoic areas illustrated in both the longitudinal and transverse scans. The pro-
forma for data collection can be seen in appendix 8. It was decided that presence of 
neurovascularisation would be recorded (and could be communicated to the player’s 
physiotherapist) but would not be used to determine group status in the study. This is 
because the majority of tendon studies simply use the presence or absence of a PTA 
to determine the health of the tendon (Cook et al., 2000; Cook et al., 2004; Gisslèn et 
al., 2007).  
 
Once an uninterrupted view of the patellar tendon was visualized, the image was 
saved to the hard disk of the ultrasound machine using the participants unique 
identifier followed by the letters L or R to distinguish which patella tendon i.e. left or 
right. The process was then repeated for the contralateral leg. Following data 
gathering, the images were transferred to a password-protected file on a University 
user account and saved in JPEG format.  
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3.12 Drop-Landing Task 
 
All participants (n=46) undertook a drop-landing task and force plate analysis to 
assess their peak vertical ground reaction force (VGRF) during a drop-landing 
movement. Ground reaction force data were collected using a commercially 
available force plate (400 Hz: Accupower Plate; Amti Advanced Mechanical 
Technology Inc., MA, USA) connected to a computer. Flight time (FT), contraction 
time (CT) and FT:CT ratio were captured using software (Accupower Software; 
Amti Advanced Mechanical Technology Inc., MA, USA), and exported to Excel 
(Microsoft) for analysis. Portable force plates have been shown to be both valid and 
reliable in measuring force-time data in jump and landing tasks (Walsh et al., 2006). 
Portable force plates were chosen because they are more accessible to training 
athletes and sporting teams. 
 
Study participants wore socks and training shoes for the data collection procedure. 
This minimized the risk of injury and had the added advantage of enabling 
comparison with other studies of sports in which jumping is a key feature e.g. 
basketball and volleyball players (as discussed in chapter two).  
 
The procedure involved performing a drop-landing from a 30 cm high platform 
situated immediately behind the portable force plate. The height of 30 cm was 
relative to the force plate (see figure 3.6). A drop-landing was used as opposed to a 
jump so that the test height for each player was standardized. If a jump protocol had 
been used, adequate comparisons between different players would not be able to be 
made.  This height would also allow adequate comparison to be made with data from 
other studies (e.g. Seegmiller & McCaw, 2003; Bisseling et al., 2007). Although 
Bisseling et al. (2007), in addition to a landing from a height of 30 cm, also used a 
landing from a height of 50 cm and 70 cm in a sample of volleyball players. It was 
decided that at this exploratory stage of investigation, where the risks of performing 
landing tasks in rugby players with patellar tendinopathy were not known (and given 
that the prevalence of patellar tendinopathy was not known), the height that was 
thought to pose the least risk to players was chosen i.e. 30 cm. 
 
 












Figure 3.6: Demonstrating set up of equipment for drop-landing task 
 
 
Players were instructed to step off the test platform with their test leg (left or right) 
first. They were instructed to land facing forward, with one foot on the force plate 
(test foot) and the other (non-test) foot parallel to the test foot. The participants were 
encouraged to land as naturally as possible (without rebounding or stumbling). After 
landing, the participant was advised to hold their stance for 10 seconds. This was to 
ensure that the anticipation of walking away from the test area did not cause the 
player to stumble. A random number generator was used to decide which leg would 
be the test leg for the first landing task. The drop-landings were then completed in 
block order, that is, if the random number generator indicated that the left leg would 
be the test leg first, then all four jumps for the left leg would be recorded first. This 
approach was adopted as to avoid the need to re-arrange the testing equipment 
between consecutive jumps. There was a rest period of 60 seconds between 
consecutive jumps, measured by an electronic countdown. This was to eliminate the 
influence of fatigue on results. It has been suggested that fatigue may increase 
patellar tendon loading by an inability of the lower limb to dissipate efficiently the 
loads sustained during landing tasks (Steele et al., n.d.).  
 
Each drop-landing was witnessed by the same observer. Before data collection, each 
participant was allowed to practice the landing protocol until both the participant and 
the observer were confident with the procedure. The observer recorded the landing 
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technique making a note that: one foot landed on the force plate, there was no 
significant stumble after landing. If the observer believed that there was any fault 
with the technique, the participant was asked to repeat the landing and the data from 
the “faulty” landing discarded. This happened once during the study. 
 
Peak Vertical Ground Reaction Force (VGRF [N]) and time to peak VGRF (tVGRF 
[ms]), data were obtained. The tVGRF was defined as the temporal difference 
between VGRF and Initial foot-ground contact (IC). IC was defined as the time when 
the VGRF first exceeded 50 N. The Loading Rate vertical ground reaction force (LR 
VGRF) was defined as the peak VGRF value divided by the tVGRF. The graph 
below is illustrative of the data produced by the computer software following a drop-

















Figure 3.7: Graphical representation of acquired ground reaction force-time curve for drop landing 




Each participant performed the drop-landing four times in total for each leg, the first 
landing for each leg being treated as a practice run and the data being disregarded. 
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The profile for each landing task was saved as an electronic copy to the computers 
hard disk. Each profile was saved using the participants unique identifier, followed 
by a letter representing the leg being measured, followed by the drop jump attempt 
i.e. 040186L(1) or 040186L(2) for a study participants first or second jump 
respectively. The letter L indicates the left leg was measured. This allowed for 





3.13 Statistical Analysis 
 
Data were analysed using IBM SPSS Statistics for Windows (version 21.0.Armonk, 
NY: IBM Corp.). The purpose of the statistical analysis that was carried out was 
geared toward answering the study questions. Participants were split into three 
groups. The first group contained players who had no clinical signs of PT on 
examination, and had tendons that were ultrasonographically normal (control group). 
The second group contained players who had no clinical signs of PT on examination. 
Their ultrasound scan demonstrated a PTA (PTA group). The third group contained 
players who had clinical examination signs consistent with PT. The ultrasound scan 
of players in this group also demonstrated a PTA (PT group). 
 
Overall prevalence of PT and PTA was determined using descriptive statistics with 
mean and standard deviation reported. The weight in the three experimental groups 
was compared using the Kruskal-Wallis test. This test was used rather than a 
parametric test because the study sample is small (see chapter 4) and the distribution 
of weight across the sample appeared to follow a bimodal distribution and not a 
normal distribution (presumably due to the two distinct groups in the sample: 
forwards and backs). In this instance, a non-parametric test is the more appropriate 
test to be used. The non-parametric test used to describe the difference between three 
or more conditions is the Kruskal-Wallis test (Dancey et al., 2012). 
 
The prevalence of PT and PTA was compared between the forwards and backs using 
chi-squared tests (χ2). This test was used because playing position is a categorical 
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variable, that is, participants could be classified as a forward or a back but could not 
be both. The chi-squared test is appropriate when assessing association between 
categorical variables (Dancey et al., 2012). 
 
The difference in peak VGRF and LR VGRF in the three experimental groups 
(control, PTA and PT) were compared using Kruskal-Wallis test. For this analysis, 
the subjects were tendons rather than players. It was decided to treat each tendon as a 
variable. Logistic regression was used to investigate whether ground reaction force 
data could be used to predict tendon status i.e. healthy or patellar tendon disease 
(PTA and PT groups combined). PTA and PT were grouped together for this analysis 
for two reasons. The first being that the sample size is relatively small. The second 
being that, if VGRF could be used to predict tendon status, it would not matter 
whether the athlete was symptomatic or not. This is because asymptomatic PTA is at 
risk of progressing to symptomatic PT (as already discussed). 
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In this chapter, the results that are presented relate to the main aims and objectives of 
the study. A summary of any statistical analysis is included. A discussion of the 




4.2 Sample  
 
There are approximately 80 age-grade academy players in Wales. Only those who 
met the inclusion criteria i.e. injury free, were invited to participate. Team 
physiotherapists provided the names of those players who were both available and 
injury free. Of those, 46 players participated in the study (Blues n=16, Ospreys n=15, 
Scarlets n=11, Newport Gwent Dragons n= 4); this gives a minimum response rate of 
57.5%, as physiotherapists did not provide data regarding the number of ineligible 
players. In order to increase the sample size, arrangements were made to include a 
further 23 players from an English region. Unfortunately on the day scheduled to test 
both the English region (and a follow up visit to the Newport Gwent Dragons 
academy) the force plate was damaged and it was not possible to reschedule. This 
has resulted in a smaller sample than desired, which is frustrating because a larger 
sample may well have resulted in statistically significant results.  
 
Of the 46 participants, 21 were forwards and 25 were backs. All participants were 
right footed. There was an average stature of 1.83 m (standard deviation 0.06), body 
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4.3 Prevalence 
 
A total of six players (13%) reported that they had been previously diagnosed with 
patellar tendinopathy or “jumper’s knee”. Of these six, four were in the PT group, 
one in the PTA group and one in the Control group. The distribution of results 
according to clinical status is exhibited by chart 4.1.  
 
 




No player had bilateral symptomatic patellar tendinopathy. In total, 21 tendons had a 
PTA (12 left, 9 right). All patellar tendon abnormalities in this study were in the 





The average VISA-P score differed according to group status: control 99.0 (3.1), 
PTA 91.2 (11.4), PT 68.9 (22.4). A Kruskal-Wallis test showed that there was a 
significant difference between groups (chi-square = 22.400, df = 2, p < 0.0001). 
Patellar	  Tendon	  Abnormality	  20%	  
Patellar	  Tendinopathy	  15%	  
Healthy	  Patellar	  Tendon	  (Control)	  65%	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When the participants are considered as two groups only, control and diseased, i.e. 
presence of PTA regardless of clinical status, there was a significant difference in 




4.4 Body Mass 
 
Descriptive statistics for body mass of the participants in each experimental group 
are provided in chart 4.2. 
 
 
Chart 4.2: Body mass according to disease group 
 
Box plot illustrates median (weighted horizontal line), interquartile range (box), 
extremes of data (whiskers) and outliers (dots). 
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A Kruskal-Wallis test showed that there was no significant difference between 
groups (chi-square = 2.468, df = 2, p = 0.291). When the participants are considered 
as two groups only, control and diseased, i.e. presence of PTA regardless of clinical 
status, the following results are obtained (table 4.1). There was no significant 
difference in mass between the control and diseased groups (p = 0.129). 
 










Mann-Whitney U Test 
Median (IQR) Median (IQR) U p-value (1-tailed) 
Mass (kg) 93.442 (19.876) 100.270 (21.261) 191.00 0.129 
 




4.5 Playing position 
 
The distribution of results according to clinical status separated by playing position is 
shown in chart 4.3 for forwards, and chart 4.4 for backs. 
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Patellar	  Tendon	  Abnormality	  24%	  
Patellar	  Tendinopathy	  24%	  
Healthy	  Patellar	  Tendon	  (Control)	  52%	  
Patellar	  Tendon	  Abnormality	  27%	  
Patellar	  Tendinopathy	  11%	  
Healthy	  Patellar	  Tendon	  (Control)	  63%	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There was no significant difference in prevalence of PT or PTA in either forwards or 
backs (χ2(2, N=46)=3.207, p=0.201). The prevalence does not change when the 
participants are considered in two groups only, control and diseased i.e. presence of 




4.6 Vertical Ground Reaction Force (VGRF) 
 
Descriptive statistics for peak VGRF and LR VGRF for tendons are provided in 
chart 4.5 and 4.6 respectively.  
 
 
Chart 4.5: Peak VGRF according to disease group 
 
Box plot illustrates median (weighted horizontal line), interquartile range (box), 
extremes of data (whiskers) and outliers (dots). 
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Chart 4.6: LR VGRF according to disease group 
 
 
Box plot illustrates median (weighted horizontal line), interquartile range (box), 
extremes of data (whiskers), outliers (dots) and extreme outliers (asterisks). 
 
 
A Kruskal-Wallis test showed that there was no significant difference between 
Controls, PTA and PT tendons for VGRF (χ2 = 2.29, df = 2, p = 0.318) or LR VGRF 
(χ2 = 0.110, df = 2, p = 0.946). 
 
When the tendons are considered in two groups only, control and diseased (the 
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Median (IQR) Median (IQR) 
VGRF (bwt-1) 2.289 (1.037) 2.120 (0.931) 
LR VGRF (force bwt-1 sec-1) 48.172 (54.733) 55.066 (49.750) 
 
VGRF, peak vertical ground reaction force; LR VGRF, loading rate vertical ground reaction force; 
IQR, interquartile range. 
 
 
The results above, suggest that it is unlikely that there is a difference between the 
diseased group and control in terms of force plate data (VGRF and LR VGRF). The 
smaller than desired sample size meant that it might in any case be difficult to detect 
such differences if they exist. However, as one of the key aims of the study was to 
assess whether ground reaction forces could be a predictor of patellar tendon disease, 
a regression analysis was undertaken. 
 
A logistic regression model was conducted to test whether VGRF predicted clinical 
tendon status i.e. whether a tendon was healthy or diseased (presence of a PTA 
regardless of clinical status). Lower peak VGRF was not significantly associated 
with diseased tendons (χ2 = 3.080, p = 0.079; table 3). This was also true for LR 
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Table 4.3: Logistic regression model predicting likelihood to suffer diseased patellar tendon 
 
 
B p Odds ratio 
 
95% confidence interval for 
odds ratio 
Lower Upper 
VGRF -0.614 0.097 0.541 0.262 1.118 
LR VGRF -0.007 0.276 0.993 0.981 1.006 
 
VGRF, peak vertical ground reaction force; LR VGRF, loading rate vertical ground reaction force. 
 
 
Data were obtained for each section of the study design as set out in chapter 2. The 
discussion of these findings is set out in chapter 5.  
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In chapter 4 the results were presented that were used to investigate the objectives of 
the study. In this chapter, the results obtained have been discussed within the context 






The response rate was 46 participants from a total possible sample of 80. When 
players were contacted directly via letter (as set out in the ethics submission), there 
were very few responses, which was very disappointing. Following this, contact was 
made with the regional physiotherapists. They were asked to approach players to 
request their participation and to hand them a copy of the letter, which set out the 
details of the study. The physiotherapists were asked to only approach potential 
participants who met the inclusion criteria. For example, they did not ask players 
who were currently injured. From this, 46 players consented to be involved. Clearly, 
involving the physiotherapists proved useful and such an approach would be 
recommended in future studies. Non-response was due mainly to unavailability or 
injury. The physiotherapists did not report that any player declined to be involved 
(apart from reasons concerning unavailability). In future, any power calculation 






As stated in the literature review, almost no studies report prevalence of patellar 
tendon disease in rugby players. However, there are studies in which PT in sports 
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that involve similar skills to rugby has been investigated (Ferretti et al., 1984; 
Ferretti et al., 1990; Lian et al., 2005). In this (Giles) study, six players (13%) from 
the sample reported a previous diagnosis of jumper’s knee or patellar tendinopathy. 
Following discussions with squad physiotherapists since the data were collected, it 
appears that this 13% may be an underestimation. This is because it appears that 
physiotherapists do not always provide the player with a label such as “jumper’s 
knee” or “patellar tendinopathy”. In some instances, they merely treat and manage 
the symptoms. In this (Giles) study, it might have been more informative to ask 
questions regarding symptoms of patellar tendinopathy suffered previously rather 
than ask about a diagnosis having been given previously. 
 
For those studies that do report prevalence of patellar tendinopathy in rugby (Brooks 
et al., 2005a, Brooks et al., 2005b, Fuller et al., 2008 and Fuller et al., 2012), there 
are issues around data collection (coding) and definition (acute versus chronic 
conditions), as has already been discussed. Since this study began, Durcan et al. 
(2013) examined the prevalence of patellar tendinopathy in elite academy rugby 
players in Ireland using almost identical data collection tools to the ones used in this 
study, which included clinical examination, ultrasound examination and VISA-P 
questionnaires. Their sample size was 83 players. It is not possible to be absolutely 
certain whether injured players were included in the study, which may explain their 
very high response rate (95.4%). The sample in Durcan et al. was very similar to the 
one in the present (Giles) study (see table 5.1). 
 
 










Mean (S.D.) Mean (S.D.) 
Mass (kg) 97.6 (11.8) 94.3 (11.5) 
Height (cm) 184.9 (7.1) 183 (5.97) 
VISA-P score 92.1 (14.5) 92.9 (14.5) 
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It can be seen that the overall prevalence of disease was similar in the two studies 
(table 5.2). The prevalence of clinically apparent patellar tendinopathy in this (Giles) 
study (15.2%) is in line with PT estimations in the general elite sporting population 
i.e. 14% (Lian et al., 2005). Durcan et al. (2013) report more asymptomatic patellar 
tendon abnormalities (26.5%) than was the case in this study (19.6%). It is worth 
noting however, that Durcan et al. use very similar, but not identical, ultrasound 
criteria for diagnosing patellar tendon abnormalities. Nevertheless, both the figure 
for asymptomatic PTA found by Durcan et al. and this (Giles) study is similar to that 
reported for the presence of asymptomatic PTA by other studies i.e. 22-32% (Lian et 
al., 1996; Cook et al., 2000, Fredberg & Bolvig, 2002; Gisslèn et al., 2005; Malliaras 















Percentage of players with patellar tendon 
abnormalities on ultrasound 
 
36.1 34.5 
Percentage of players with patellar tendon 
abnormalities on ultrasound and with clinical 








Four players (8.7%) had bilateral disease according to US criteria in this (Giles) 
study. Again, this is similar to that reported by Durcan et al (9.7%). It is not possible 
to compare this with other studies because they either don’t report it or report only in 
terms of total number of tendons. Durcan et al. report that the percentage of tendons 
that had an abnormal ultrasound appearance was 22.9%, compared with 21.8% in 
this (Giles) study. This makes the findings in both studies similar.  
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Both this (Giles) study and the Durcan et al. study involve academy rugby players 
and report a prevalence of patellar tendon disease at approximately 35%. This gives 
some reassurance that the findings in this (Giles) study are a reflection of reality. 
Nevertheless, the difference in prevalence in the two studies involving academy 
players from that of studies reporting prevalence in senior squads is substantial. For 
example, Brooks et al. (2005a, 2005b) report only three incidences of PT in 546 
senior rugby players over two years. The reasons for this need to be explored but this 
may be because of two explanations. 
 
The first explanation for the difference in reported prevalence may be that there is no 
real difference but the scale of the problem had been underestimated in previous 
studies because of problems with injury definition and coding, the diagnosis of 
patellar tendon disease and in the reporting of the condition. It is likely that under-
reporting has resulted in such low prevalence rates because studies investigating 
prevalence in senior players have used injury self-reporting. The problems of self-
reporting in chronic injuries, such as patellar tendinopathy, have already been 
discussed but include the fear of being diagnosed as injured and its implications (not 
playing, salary, career ending etc.). Perhaps, most seriously of all, given the findings 
in this (Giles) study and that of Durcan et al. (2013), the self-reporting approach to 
injury management and prevention is one which is not pro-active, i.e. players have to 
be sufficiently symptomatic before a diagnosis is attempted and thus reported. As 
many athletes are able to continue their sporting activities despite the chronic pain of 
patellar tendinopathy, they are often not included in incidence rates as new injuries 
that cause time-loss from sport (Scott et al., 2013). A more appropriate method for 
investigating overuse injuries has been recommended by Bahr et al. (2009) and 
advocated in the consensus statement from the International Scientific Tendinopathy 
Symposium in 2012 (Scott et al., 2013). Bahr made two main recommendations. The 
first is that “prevalence and not incidence should be used to report injury risk” (as 
was discussed in chapter 2). This is because incidence is an inappropriate measure 
for a condition that is both chronic and has insidious onset. The second 
recommendation is that “severity should be measured based on functional level and 
not time loss from sports” because athletes may be able to carry on playing and 
training despite the pain of overuse injuries. The VISA-P would be an example of a 
measure based on functional level in those with patellar tendinopathy.   
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The second explanation for the difference in reported prevalence of patellar tendon 
disease in rugby is that there is a true difference between the two populations studied 
(academy rugby players and senior rugby players). This may be due to age or 
training practices. On entering the academy system, age grade players are exposed to 
intensive training regimes, which exposes the athlete to increased load. Such a 
sudden increase in load (e.g. increased volume, intensity or frequency of training), 
which occurs when athletes are promoted from junior to senior levels, has been 
suggested as a possible risk factor for PT (Reeser et al., 2006 [citing personal 
communication from L Oystein and R Bahr 2006]. This supports the maxim that 
“tendons don’t like rest or change” (Jill Cook, International Scientific Tendinopathy 
Symposium workshop, 2012). After discussion with the club physiotherapists 
involved in this thesis, it transpired that academy athletes might have more training 
and playing commitments than senior players. For example, a regional academy 
player may also be playing for (and training with) a local team and a university team. 
It follows that the player may be exposed to a load that is not fully appreciated by the 
regional physiotherapists, coaches, conditioners etc. Since tendon overload has been 
implicated as a critical factor in the development of patellar tendon disease, this 
needs to be given due consideration. Unfortunately, this (Giles) study was not 
designed to look at the difference in training practices between academy players and 
senior players. Despite this, it was worth considering whether the difference in 
prevalence in our (Giles) study, compared to epidemiological studies of senior 
players, may be due to the age and / or training practises of the athletes involved. 
 
There was an opportunity to investigate further the cause for the difference in the 
reported prevalence. This is because the clinician who performed the ultrasound 
scans for this (Giles) study is also the physician to a Welsh regional rugby club. It is 
his normal practice to perform ultrasound scans on the squad. Routine ultrasound 
scans were performed on 35 senior players. The ultrasound scans were performed 
using the same equipment, the same methods and the same diagnostic criteria as used 
in this (Giles) study. Data were collected for 35 players and checked for accuracy. 
Permission was sought to release anonymised, aggregated data from the ultrasound 
scans so that comparisons could be made with this (Giles) data. The clinician’s 
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normal practice to ensure that newly discovered injuries were dealt with was 
undertaken.  
 
The results that follow help to inform the hypothesis that the difference in prevalence 
between academy players and senior players is due to different training regimes. 
However, it must be emphasized that this adjunct study was not part of the study 
design for this thesis. Informative though the results are, there needs to be a formally 
designed study that investigates the prevalence of PT in senior players, and compares 
this with the prevalence in academy rugby players. The results are summarised in 
table 5.3.  
 
 













Percentage of players with previous diagnosis 




Percentage of players with patellar tendon 
abnormalities on ultrasound 
 
22.9 34.5 
Percentage of players with patellar tendon 
abnormalities on ultrasound, in the absence of 








The results from the senior squad are similar to the academy players. There is no 
significance difference in the prevalence of patellar tendon disease between the two 
groups (χ2(1, N=81) = 1.356, p=0.2443). Therefore, this suggests that the prevalence 
of patellar tendon disease in senior rugby athletes has been previously 
underestimated. This is likely due to the problem with injury definition and coding 
(as has already been discussed). It gives further weight to the argument for using 
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alternative methods to quantify patellar tendon disease (and other overuse injuries) 
by using prevalence in prospective studies and measuring loss of function. 
 
Similar to Durcan et al. (2013), there was a statistical significant difference between 
VISA-P score for control and diseased groups. These results should be interpreted 
with caution in terms of using VISA-P as a screening tool for patellar tendon disease. 
If the VISA-P was used for screening purposes, the symptoms reported on the 
questionnaire might not necessarily be attributed to PT. Therefore it lacks specificity. 
For example, the symptoms may be caused by other pathology (arthritis, recent 
trauma etc.). In addition, as is discussed in chapter 2, there may be a problem of 
under-reporting, which would result in false negatives. Furthermore, in this thesis, 
the VISA-P scores in the diseased groups have high standard deviations (11.4 and 
22.4). This may be due to the subjective nature in the way which symptoms are 
experienced. This could also be a factor that undermines the utility of the VISA-P 
tool for screening purposes.  
 
As documented in the section on ethical considerations, each player was informed of 
the findings of their clinical examination and ultrasound scan. Where abnormalities 
were present, the participants were informed that it would be beneficial to them that 
the findings were shared with their regional physiotherapist so that appropriate 
clinical management could be undertaken. Each player concerned consented to this. 




5.4 Body mass 
 
The presence of disease was cross-tabulated with body mass. It was considered that 
there could be a relationship between body mass and the presence or absence of 
disease.  
 
There was no relationship between body mass and presence of disease (p=0.129). 
This finding resembles that from Durcan et al. (2013) who also found no relationship 
between the two variables (p=0.337). In contrast, studies of patellar tendinopathy in 
	   65	  
athletes from other sports, e.g. volleyball, had different results (Lian et al., 2003, 
p=0.05; Malliaras et al., 2007, p<0.01). Interestingly, the sample size in Lian et al. 
(n=47) is very similar to that of this study (n=46). However, the authors diagnosed 
patellar tendon disease via clinical methods only (with no reference to who did the 
examinations) and did not use musculoskeletal imaging. The authors did not identify 
players with patellar tendon disease based on ultrasound criteria and the results can 
therefore not be reliably compared with those in this study. Malliaras et al. (2007) 
defined patellar tendons as abnormal according to similar criteria as this (Giles) 
study, and from a sample of 73 males reported that weight was associated with 
abnormal imaging of the patellar tendon (p<0.01). This is counter-intuitive because 
the players in this (Giles) study and Durcan et al. (2013) had body mass greater than 
those in the Malliaras et al. (2007) study. This means that a factor other than body 
mass per se might have been responsible for the Malliaras et al. finding. This may be 
the result of the specific characteristics of each sport i.e. both sports involve 
eccentric loading, however volleyball is characterized by high frequency of maximal 
jump activities whereas rugby is characterized by a lower frequency of maximal 
jump activities. In addition, the different surfaces on which the two sports are played 
are likely to place different demands on the extensor mechanism of the knee. For 
example, Lian et al. (2005) cite Bahr and Reeser (2003) who showed that the 
prevalence in jumpers knee among elite beach volleyball players was only 9% which 
is considerably lower than for indoor volleyball players. They argued that the 
difference in prevalence of PT between the two sports when played on different 
surfaces is that jumping and landing in soft sand are less demanding on the patellar 
tendon than is jumping on indoor playing surfaces. Whereas indoor playing surfaces 
are designed to reduce the occurrence of overuse injuries by infrastructure that 
includes an element of shock absorption nevertheless, the playing surface is non-
compliant wood. The rugby players in this (Giles) study played their competitive 
games on grass. Furthermore, personal communication with the regional academy 
physiotherapists revealed that the players in this (Giles) study had over 90% of their 
training sessions on grass. This could explain the difference in the prevalence of PT 
found in this thesis compared to those studying indoor volleyball but this hypothesis 
would need to be investigated in future studies. 
 
 
	   66	  
5.5 Playing position 
 
One of the risk factors identified for developing PT was position played with the 
proposition that forwards would be more at risk than backs. This is because 
traditionally forwards have greater body mass than backs, and are more likely to 
engage in maximal jump activities. In this (Giles) study, the results demonstrate no 
relationship between playing position and presence of patellar tendon disease 
(p=0.094). The only study that can be made reference to in relation to this finding is 
one by Lian et al. (2003), who found a statistically significant difference in the 
prevalence of patellar tendinopathy according to playing position in male volleyball 
players. However, it has already been discussed that the authors defined patellar 
tendinopathy without the use of ultrasound imaging and therefore it is difficult to 




5.6 Vertical Ground Reaction Force 
 
Given that there is some evidence that athletes with patellar tendon disease exhibit 
different VGRF during landing tasks compared to their healthy counterparts, together 
with the speculation by Richards et al. (2002) that this easy to perform test may be 
used as a predictor of the presence or absence of disease, the relationship between 
VGRF and tendon status was examined.  
 
There was no difference in peak VGRF or LR VGRF between controls and those 
with diseased patellar tendons (regardless of whether there were clinical signs or 
not). The logistic regression analysis was unable to predict tendon status in relation 
to ground reaction forces from drop-landings. These findings are counter to initial 
expectations. Once again, not reaching statistical significance might be the 
consequence of the small sample size. Initially, this was considered to be surprising 
because Fietzer et al. (2012) in a sample of only 18 elite dancers, found a significant 
difference in the peak VGRF between those with clinically diagnosed PT and 
asymptomatic controls (p<0.001). Further analysis of this paper revealed that it was 
likely that non-standardisation of both athlete and technique were factors at play, 
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which predisposed to statistically significant results being obtained. For example, 
males and females were included in the sample. In addition, participants were 
recruited from at least five different dance forms e.g. jazz, ballet etc. Also, the 
landing technique was not standardised. Participants were instructed to jump at full 
performance level, the height of which would have been different for each 
participant. The rugby participants in this (Giles) study all undertook a drop landing 
from an identical height (30 cm) to ensure that any difference detected in VGRF and 
LR VGRF would have mostly likely been to the presence of disease and not due to 
the height from which the landings occurred. 
 
Bisseling et al. (2007) measured VGRF in a drop-jump protocol in their study into 
patellar tendinopathy in volleyball athletes. They reported no difference between 
athletes with patellar tendinopathy in peak VGRF but found a strong tendency 
(p=0.05) in higher LR VGRF when compared with controls. Again, the authors use a 
clinical diagnosis of PT to decide group membership. As such, the difficulties of 
comparing these results with this (Giles) study have already been discussed. The 
authors used a cross-sectional retrospective study design. Out of the 89 male 
volleyball athletes who completed the initial questionnaire, only 24 players were 
invited to take any further part in the study. Furthermore, group allocation (control, 
previous jumper’s knee or recent jumper’s knee) may have been influenced by recall 
bias. Coupled with the slightly different landing task involved, may explain the 
difference in the result regarding LR VGRF.  
 
Edwards et al. (2010) used a stop-jump task to measure VGRF in controls and 
athletes with a PTA present on ultrasound imaging (but who are asymptomatic). 
There is no reference to the sports that these athletes play regularly apart from stating 
that their sports involve “repetitive landing”. There could potentially be a wide range 
in the skills that these athletes possess. The vertical landing from a stop-jump task is 
not standardised unlike a drop-landing task. The vertical landing phase of the stop-
jump task took place from a height that was, on average, higher than the 30 cm 
standardised height in the Giles study (50.5 +/- 5.9 cm for controls and 52.0 +/- 6.0 
cm for PTA in Edwards et al.). The relatively small sample size (n=14, high standard 
deviations), and potentially involving athletes from a range of different sports mean 
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that the results must be interpreted with caution and cannot be directly compared 
with this (Giles) study.  
 
However, the height of the drop-landing task (30 cm) in this (Giles) study might 
have been too low to detect any difference in VGRF due to patellar tendon disease. 
Other researchers have used greater heights from which to measure VGRF from 
landing tasks e.g. 50 cm and 70 cm, but these studies did not include rugby athletes. 
This issue was carefully considered (chapter 2) and the height that was thought to 
pose the least risk to players was chosen i.e. 30 cm. Following the drop-landing 
tasks, none of the participants reported pain or discomfort with the procedure. The 
game of rugby involves landing from heights greater than 30 cm. For future studies, 
the desirability of using greater heights for drop-landing tasks should be considered. 
It is premature to discount force plates and VGRF from having a role in screening for 






Given the current literature and the study objectives, it was surprising that no 
relationship was found between patellar tendon disease and key variables. This may 
be due to a smaller than desired sample size. However, if there is no relationship 
between the investigated key variables and patellar tendon disease, and this is 
considered alongside the high prevalence of the disease (validated by at least one 
other study), then all players must be considered to be at risk of developing the 
condition. It could also be the case that another variable, not yet considered, is the 
cause of high prevalence of patellar tendinopathy in rugby populations; e.g. load 
(high intensity, volume or frequency of training regimes). This should be considered 
for future study.  
 
The prevalence rate of PT in this study and that of Durcan et al. (2013) is 15.2 and 
9.6 % respectively. This is a high prevalence rate. However, it is based only on those 
athletes who were included in each study. For valid and meaningful prevalence rates, 
it is necessary that the entire at risk population be known accurately. The population 
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at risk is a group of people who share a characteristic that causes each member to be 
susceptible to a particular condition – or the number of people capable of 
experiencing the outcome of interest, i.e. patellar tendinopathy. With current data, it 
is impossible to be confident that the prevalence rates reported can be extrapolated to 
the population as a whole. That population might include all elite (or sub-elite) rugby 
players that may have to be divided into senior and youth athletes. The reason for 
caution is that prevalence rates are the most useful statistic both to quantify the size 
of the problem in a population and to plan services including disease management 
and prevention. As Chalmers (2002) argued, over a decade ago, we need to move 
from the maxim that “injury is just part of the game”, to the maxim, “injury 
prevention is just part of the game”. To realise this ambition, further studies to 
increase confidence levels in the prevalence rates discovered so far are required. 
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Chapter 6: Conclusions 
 
 
This section on conclusions is derived from findings from both the literature review 
and the empirical work undertaken. This study of a sample of rugby athletes has 
provided insights into patellar tendinopathy: its prevalence, definition and the issues 
with coding. Hitherto weaknesses in all three may have led to an underestimation of 
the size and scope of the condition. To date, the majority of epidemiological studies 
into rugby report injury incidence rates and not prevalence. Often, chronic, overuse 
injuries, which have an insidious onset; of which patellar tendinopathy is one 
example; are not included in incidence rates as “new injuries” and this probably has 
resulted in under-reporting. Current methods to define injury, such as time-injury 
loss models, are not appropriate for patellar tendinopathy (or other overuse injuries). 
Rather, prospective models recording pain or function loss as a result of injury 
should be used. In addition, it is also essential that injury coding, which would 
inform prevalence studies, is valid. For example, injury codes should be specific and 
consistently used. This would overcome the problem of the vague way in which 
tendinopathy results have been presented in the literature which range from “knee 
injuries” to “tendon rupture / tendinopathy / bursitis” where the joint affected may or 
may not be specified.  
 
The findings suggest that patellar tendinopathy is a significant problem in rugby 
union, with 15% of academy rugby players suffering clinically apparent patellar 
tendinopathy. A further 20% (35% total) of academy rugby players show patellar 
tendon abnormalities on ultrasound screening. Fortuitously, a contemporaneous 
study (Durcan et al., 2013) investigating patellar tendinopathy in rugby players has 
reported similar results. Both this (Giles) study and Durcan et al. report a higher 
prevalence than previously reported in the rugby literature, but consistent with the 
level of prevalence in sports that have been traditionally associated with the 
condition and which share similar characteristics to rugby i.e. jumping, sprinting and 
cutting. Thus, it has provided data regarding the prevalence of the disease, the first 
step in sports injury prevention models.  
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It was hypothesized that there would be a relationship between patellar tendinopathy 
and key variables (mass, playing position or VGRF from a drop-landing task). No 
statistically significant relationship between these variables was found. There are 
several possible explanations for this: 
 
1. The small sample size. Several results were very close to being statistically 
significant and it might be that in a larger sample statistically significant 
results would be obtained. Given the high prevalence of disease, it is another 
reason for repeating the study with a bigger sample.  
2. It may be that the height of the drop-landing task was inadequate to detect 
true differences in VGRF between players with healthy tendons and diseased 
tendons. Consideration should be given to repeating the study using a drop-
landing task from an increased height i.e. 50 cm and 70 cm. 
3. That there is no relationship could mean that all players, regardless of 
variables such as playing position, weight etc. must be considered to be at 
risk of developing PT. This may be due to an unknown factor e.g. load / 
training. The implications of this need careful consideration. 
 
 
Despite the smaller than desirable sample size, a high prevalence rate of disease (one 
in three) was found and this was not related to mass or playing position. This finding 
was mirrored in a study carried out simultaneously in Ireland. Until more 
sophisticated prevalence studies can be conducted, it is reasonable to conclude that 
all players carry a risk of developing patellar tendon disease and further work to 
ensure that the population at risk is accurately captured is needed in order to provide 
a valid basis from which to perform future prevalence studies. There is a suggestion 
(from an informal, small set of data) that the prevalence of patellar tendinopathy in 
senior players resembles that found in the academy players that were included in this 
study. Given the career limiting possibilities of the condition, this finding has 
implications for the desirability for appropriate screening and research into risk 
factors and further studies are warranted. 
 
This study should be repeated with a larger sample size because several of the results 
obtained approached statistical significance. It may well be possible to demonstrate 
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statistical significance with a larger sample, which would obviously add confidence 
to the findings.  
 
Other conclusions in relation to sample are as follows: 
 
1. Recruitment to the study proved very difficult until the cooperation of 
regional physiotherapists was obtained. Tactics such as this need to be 
adopted in future because one of the biggest causes of bias in research is a 
low response rate. 
 
2. The sample size would have been bigger if the force plate equipment had 
not broken on the day scheduled to assess a further 23 players. In future, 
it is recommended that access to back up equipment, where possible, is 
essential. 
 
3. There were no studies into patellar tendinopathy in rugby prior to the 
studies undertaken by Giles and Durcan et al. (2013), which occurred 
simultaneously. As a consequence of the results reported, future studies 







The main limitations of this study relate to the smaller than desired sample size that 
was achieved.  As has already been mentioned, due to the absence of pre-existing 
data regarding patellar tendinopathy in rugby players, it was difficult to undertake a 
power analysis prior to commencing the study. If possible, this would have given 
valuable information to suggest the sample size required to detect differences 
between those with patellar tendon disease and those without patellar tendon disease. 
As this was not possible, the protocols employed to detect true differences between 
those players with and without patellar tendon disease may have been compromised.  
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Study participants were required to provide information on whether they had 
previously suffered with jumper’s knee or patellar tendinopathy. This may have been 
a source of recall bias and led to a misestimation of the scale of patellar 
tendinopathy. For example, a player may have been treated for patellar tendinopathy 
previously but had not been made aware of the diagnosis. One way in which this 
could have been avoided would have been to request medical notes from the players’ 
medical team, however this would rely heavily on adequate medical notes being 
made contemporaneously. Adopting this approach would lead to ethical issues that 
would need careful consideration. However, since the examining clinician did not 
have access to this data (regarding previous diagnosis), this potential source of recall 
bias would not have influenced group membership i.e. whether a player was 




Recommendations for practice and research 
 
Notwithstanding these limitations, the results presented in chapter 4 give rise to 
several recommendations for clinical use and for areas of future research. The 
recommendations for clinical practice and sports injury prevention are as follows: 
 
1. Health professionals looking after rugby players (particularly age-grade 
players as they progress through the academy system) should be aware of this 
high prevalence and be actively looking for symptoms and signs of patellar 
tendinopathy. Players should be instructed as to the symptoms of patellar 
tendinopathy and encouraged to report such symptoms to their medical team 
or physiotherapist.  
 
2. All elite rugby players, particularly age-grade players, should have their load 
monitored and managed appropriately. 
 
3. Due to the high prevalence of asymptomatic PTA found in this study, 
coupled with the higher risk of athletes with PTA going on to develop 
symptoms of patellar tendinopathy, it is desirable to screen all elite rugby 
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players. Given that this study (with its smaller than desired sample size) does 
not support the use of VGRF (from drop-landing tasks at heights of 30 cm) in 
the screening for patellar tendon disease, and in the absence of an alternative 
method at this time, the method of screening for patellar tendon disease 
should be ultrasound screening. Despite the difficulties associated with this 
recommendation (particularly the expense and expertise required) a balance 
has to be struck between health of the athlete and expense. In order to support 
the medical team, recommendations for ultrasound screening to be made 
available should be made to rugby governing bodies.  
 
The recommendations for future research are as follows: 
 
4. The prevalence of patellar tendon disease in rugby has been found to be 
higher than previously thought. To ensure that the population at risk is 
accurately captured, the study should be repeated with a larger sample size. 
This should include senior rugby players (i.e. not just those attached to 
academies). This would improve the external validity of the results. It would 
also clarify whether any differences in prevalence exist for both age-grade 
and senior athletes. For future studies, it will be possible for power 
calculations to determine the required sample size, because this (Giles) study 
has provided data on mean and standard deviation for key variables. 
 
5. Future studies should consider mechanical overload as a factor that 
contributes to the development of patellar tendon disease in rugby athletes. 
The definition of overload might be different for age-grade players and senior 
players. By collecting data on variables such as frequency, volume of 
training, playing intensity etc. the potential effects of overload can be studied 
appropriately. Notational analysis methods would facilitate such 
investigations. 
 
6. When investigating prevalence of patellar tendinopathy, it would be 
favourable to ask players whether they had suffered with the symptoms of 
patellar tendinopathy previously rather than ask whether they had been given 
a diagnosis of the condition. Physiotherapists or clinicians may merely treat 
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the symptoms of patellar tendinopathy rather than explain the diagnosis to the 
player concerned. Adopting this approach (of enquiring about symptoms 
rather diagnosis), would likely result in a more accurate estimation of the 
lifetime prevalence of patellar tendinopathy. 
 
7. As no participant, including those with patellar tendon disease, found the 
drop-landing task uncomfortable, future research investigating VGRF in 
rugby athletes should use a height of greater than 30 cm for the drop-landing 
task.  
 
8. The findings to date, do not allow predictions to be made about which players 
with asymptomatic PTA go on to develop symptomatic patellar tendinopathy. 
It is recommended that the players identified as having an asymptomatic PTA 
in this study should be invited to participate in a follow up study to determine 
how many players with PTA (identified on ultrasound) went on to develop 
symptoms. It would then be possible to explore whether any relationship 
existed between those that went on to develop symptoms and their baseline 
VGRF data. Whilst being mindful that the numbers involved in this sample 
subset would be small, any insights would add strength to the 
recommendation to repeat the research with a larger sample. 
 
9. It is not known whether other lower limb injuries predispose athletes to 
developing patellar tendinopathy. Studies often list previous injuries as an 
exclusion criterion as a previous injury may act as a confounding variable. 
Since injuries are becoming increasingly common among athletic 
populations, future studies should aim to investigate whether there is an 
association between previous injury and patellar tendinopathy.  
 
10. As the prevalence of patellar tendon disease is high, and given the career 
limiting possibilities of the condition, there is a need for further high quality 
research into patellar tendon disease in rugby athletes with specific emphasis 
on consistency in diagnosis and coding. If this were achieved, it would enable 
reliable large data sets to be available for analysis. 
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Dear (manager / medical staff) 
 
 
The University of Glamorgan is about to launch research into a new method 
of screening for patellar tendinopathy. It is one of the research topics 
sponsored by the JPR Williams trust. 
 
It will investigate whether force plate testing would be a suitable method for 
screening for this common condition. This would hopefully allow the problem 
to be picked up before symptoms start and would avoid both impaired 
performance and time off with injury. 
 
Force plate analysis is a simple test which can potentially be performed at 
club training grounds and would avoid the need for players to travel to a 
specialist medical centre unnecessarily. 
 
The research will involve inviting players to undergo a force plate analysis, 
answering a questionnaire and having an ultrasound scan of their patellar 
tendons. The whole process should take no more than 40 minutes per player. 
Neither the force plate testing or ultrasound scan causes any discomfort. 
 
Any player (with their consent) identified as having a potential problem with 
their patellar tendon will be referred to a sports medicine physician and/or 
club physiotherapist for further investigation and management. 
 
All elite academy players in Wales will be offered to be involved in the 
research, and we would initially aim to visit yourselves and discuss the 
opportunity with both you and the eligible players. We will also use this time 





Dr M Giles 
 
JPR Williams Research Fellow 
University of Glamorgan 
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Appendix 3. Participant Information Sheet 
 
Participant Information Sheet 
 
 





You are being invited to take part in a research study. Before you decide 
whether or not to be involved, you will need to know why you are being asked 
to take part and what the process involves. Please take time to read the 
following information carefully. Please ask us if there is anything you are not 
sure about or if there’s anything you would like to know more about. 
 
 
What is the purpose of the study? 
 
Patellar tendinopathy or jumpers knee is commonly seen in rugby players 
and can limit or even end a promising professional career. It is caused by 
repetitive movements such as jumping or sudden changes in direction while 
running. It results in pain felt over the lower part of the knee. 
 
Patellar tendinopathy often causes the player to adapt the way they move, 
jump and run. Patellar tendinopathy increases the possibility of a potentially 
serious injury.  
 
A diagnosis of jumpers knee is usually made by clinical examination by a 
doctor or physiotherapist. It is confirmed with an ultrasound scan of the knee. 
The changes on this ultrasound scan can often be seen before the athlete 
develops pain. However, ultrasound scanning requires a great deal of cost 
and expertise. 
 
It may be that those athletes with degenerative patellar tendons have 
different forces exerted on them by the ground compared with athletes 
without these degenerative changes. This can be measured using a force 
plate.  
 
The aim of this study is to investigate whether force plates may be used as a 
more accessible method than ultrasound in screening for signs of patellar 
tendinopathy. This would allow players to be screened and treated for this 
condition before they develop pain. 
 
 
Why have I been chosen? 
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Patellar tendinopathy commonly affects rugby players as well as other 
athletes - more commonly around adolescence. As such, all age grade elite 




Do I have to take part? 
 
It is up to you whether or not to take part. There are no penalties to refusing 
to take part and you do not have to give a reason. If you agree to take part, 
you will be given this information sheet to keep and you will be asked to sign 
a consent form to show you agree to take part. You are still free to withdraw 
from the study at any time. 
 
 
What will happen to me if I take part? 
 
If you agree to take part you will be invited to attend the University of 
Glamorgan at a time convenient to you. This is the only visit you will make. 
This visit will be split into three stations.  
 
Station 1: A short questionnaire (approx. 5 minutes) 
This will involve giving details regarding your date of birth, whether you are 
left or right handed, preferred playing position and answering some questions 
regarding whether or not you experience knee pain. 
 
Station 2: Examination and scan of your knees by a doctor (approx. 10 
minutes) 
This will involve feeling the lower part of your knee for pain and asking you to 
do some simple movements. This section will end by having an ultrasound 
scan of your knees, this is a painless procedure. There is no discomfort 
experienced with an ultrasound scan. 
 
Station 3: Force plate analysis (approx. 15 minutes) 
This will involve stepping off an elevated platform on to a force plate. This 
force plate will measure the force generated when your feet touch the 
ground. You will be asked to do this three times. No discomfort is 
experienced with this procedure. 
 
 
What else do I need to do? 
 
There are no restrictions to your lifestyle or changes in your training 
programme that you need to make in order to take part in this study. 
 
 
What are the possible disadvantages and risks of taking part? 
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There are no foreseeable risks to taking part in this study. 
 
 
What are the benefits of taking part? 
 
This study may identify those athletes with patellar tendinopathy. If this 
happens, we will inform your club physiotherapist (with your permission) so 
that they can start treating you for the condition.  
 
We cannot guarantee that taking part in this study will help you as an 
individual, but the information we get from the study may help to screen 





All travel costs incurred will be refunded by the University of Glamorgan 
 
 
Will my taking part in the study be kept confidential? 
 
Yes, all information collected during the study will be kept strictly confidential. 
Each participant will be given a unique research code known only to the 
research team. Any data which is disseminated will have your identifiable 
information removed so that you cannot be traced. 
 
 
What will happen to the results of the research project? 
 
The results of the study will form part of a thesis. The results may also be 
submitted for publication in scientific journals and presented at scientific 
meetings. No participant will be identified in any publication of the results. 
 
The data collected in this project may be used in subsequent or additional 
ethically approved projects but no individual shall be named. The results will 
be made available to your region and you will be invited to a seminar in which 
the results are to be presented. 
 
 
Who is organising and funding the project? 
 
The project is being organised by the University of Glamorgan and joint 
funded by the University of Glamorgan and JPR Williams Trust. 
 
 
Who has reviewed the project? 
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Who should I contact for further information? 
 









For specific information regarding this project, in the first instance you can 
contact 
 
Dr Matthew Giles     email: matt.giles@me.com 
Professor Gareth Jones (supervisor) email: 
gareth.jones@doctors.org.uk 
Morgan Williams (supervisor)   email: mdwillia@glam.ac.uk 
Professor Richard Mullen (supervisor)  email: rhmullen@glam.ac.uk 
 
If you have any concerns during the study or if there’s anything you are 
unhappy about, you may contact the University of Glamorgan complaints 
procedure.	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Appendix 4. Consent form 	  
 




I agree to take part in the above faculty of health, sports and science 
(University of Glamorgan) research project. I have had the project explained 
to me and I have read the participant information sheet.  
 
I understand that agreeing to take parts means that I am willing to: 
 
 Answer a questionnaire giving information on general 
characteristics, whether I experience any symptoms of patellar 
tendinopathy and how (if applicable) they affect my quality of life 
 Receive an examination of the knee by a Sports Medicine doctor 
 Receive an ultrasound scan of the knee 






The information collected for the study will be held and processed only for the 
purposes of research. 
 
I understand that any information I provide is confidential, and that no 
information that could lead to the identification of any individual will be 
disclosed in any reports on the project, or to any other party. No identifiable 
personal data will be published. The identifiable data will not be shared with 
any other organisation or individual.   
  
I agree to the University of Glamorgan collecting and processing this data. I 
understand that the data will be used only for the purpose(s) set out in this 
statement and my consent is conditional on the University complying with its 
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Withdrawal from study  
  
I understand that my participation is voluntary, that I can choose not to 
participate in part or all of the project, and that I can withdraw at any stage of 
the project without being penalised or disadvantaged in any way. Should I 
decide to withdraw from the study this decision will not be communicated to 




I agree that the data collected in this project may be used in subsequent or 
additional ethically approved research projects. I understand that no 
identifiable personal information will be shared or published. 
  
  
Name:           ......................................................................... (please print) 
Signature:  .......................................................................…… 
Date:   ............................. 
  
 
Independent witness to participant’s voluntary and informed consent: 
  
I believe that ………………………….. understands the above project and 
gives her/his consent voluntarily 
  
Name:           ........................................................................ (please print) 
Signature .................................................................................. 
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2. Do you have pain walking downstairs with a normal gait cycle? 
3. Do you have pain at the knee with full active non-weight-bearing extension? 
4. Do you have pain when doing a full weight bearing lunge? 
5. Do you have problems squatting? 
6. Do you have pain during or immediately after doing 10 single leg hops? 
! !Faculty of Health, Sports and Science, University of Glamorgan !
!Victorian Institute of Sport Assessment (VISA-p) questionnaire !!!!!
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Appendix 6. Experience of clinician conducting clinical examination 
and undertaking ultrasound scans of patellar tendons 
 
 
Professor Gareth Jones 
 
Qualifications 
MB BCh  1976 
MRCP (UK)  1984 
MRCGP  1986 
MSc (SEM)  2003 
 
Membership and affiliations 
FFSEM (I)   2004 




MSc (SEM)  Bath University 2003 
Musculoskeletal Ultrasound Intervention course 2011 
Musculoskeletal Ultrasound (Philips Medical systems) 2006 
 
 
Current Practice and experience 
 
Specialist doctor in cardiology (NHS) – one session per week 
1998-present 
General cardiology (including echocardiogram) and manages rapid access chest pain 
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Specialist doctor in in orthopaedics (NHS) – two sessions per week 
2013-present 
Provides clinical assessment, near patient musculoskeletal ultrasound and ultrasound 
guided injections. Routinely undergoes audit comparing pre-operative ultrasound 
reports with findings at operation 
Undergoes 6 weekly peer review MSK-US with consultant radiologist 
 
 
Cardiff Blues head sports physician – three sessions per week (and matches) 
 
Provides cardiac screening (including echocardiograms) to WRU – national seniors,  
7s, and national age-grade squads 
 
Course director, author and tutor – online diploma / MSc in Sports & Exercise 
Medicine (University of South Wales)  
 
Provides clinical expertise and support to SEM research studies at the University of 
South Wales 
 
Bath University Tutor and examiner for Dip/MSc SEM 
 
Provides sports medicine services to team sport at the University of South Wales 
 
Chief Medical officer Gemau Cymru (2011-present) 
 
Welsh Rugby Union Sports physician 1993-2013 
 
Ospreys rugby sports physician (2003-2012) 
 
Commonwealth Games council for wales (1998 – Team doctor, 2002-2010 – Chief 
medical officer) 
 
Tumble RFC Team doctor (1987-1995) 
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  Left side:    Yes          No 
  
  Right Side:  Yes          No 
Pain in palpation over patellar tendon (consistent with PT)? 
  Left side:    Yes          No 
  
  Right Side:  Yes          No 
Clinically does this player signs consistent with patellar tendinopathy? 
  Left side:    Yes          No 
  
  Right Side:  Yes          No 
!Faculty of Health, Sports and Science, University of Glamorgan !
Assessment by Sports Physician 
!!
Pain over inferior pole of patella (consistent with PT)? 
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Left side:    !
Right side:  
Tendon width (mm)     !
Tendon width (mm)     
.................... !
.................... 
Any hypoechoic areas evident (on both views)? 
  Left side:    Yes          No 
  
  Right Side:  Yes          No 
Inhomogeneity present? 
  Left side:    Yes          No 
  
  Right Side:  Yes          No 
Evidence of neovascularisation? 
  Left side:    Yes          No 
  
  Right Side:  Yes          No 
On ultrasound, does this person have a PTA? 
  Left side:    Yes          No 
  
  Right Side:  Yes          No 
!Faculty of Health, Sports and Science, University of Glamorgan !
Ultrasound scan of patellar tendon 
